var title_f2_26_2464="Posterior tibiofibular ligament and inferior transverse ligament";
var content_f2_26_2464=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F66189&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F66189&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Posterior tibiofibular ligament and inferior transverse ligament",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 302px; height: 512px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posterior view of the key ligamentous attachments between the distal tibia and fibula. The posterior tibiofibular ligament (PTiFL) and the inferior transverse ligament (ITL) attach the posterolateral tibila tubercle to the posterior aspect of the fibula.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_26_2464=[""].join("\n");
var outline_f2_26_2464=null;
var title_f2_26_2465="Bone scan stress fracture distal fibula";
var content_f2_26_2465=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F67194&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F67194&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bone scan showing a stress fracture of the distal fibula",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 434px; height: 648px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Scott M Koehler, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_26_2465=[""].join("\n");
var outline_f2_26_2465=null;
var title_f2_26_2466="Fetal echocardiogram AV canal defect";
var content_f2_26_2466=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F86330&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F86330&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Fetal echocardiogram of atrioventricular canal defect",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 397px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fetal echocardiogram with common atrioventricular valve (AVV) separating a common atrium (CA) and ventricles.",
"    <div class=\"footnotes\">",
"     RV: right ventricle; LV: left ventricle.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_26_2466=[""].join("\n");
var outline_f2_26_2466=null;
var title_f2_26_2467="Genetic pleiotropy";
var content_f2_26_2467=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F62239&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F62239&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 557px\">",
"   <div class=\"ttl\">",
"    Genetic pleiotropy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 537px; height: 346px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In Mendelian randomization, the effect of the genetic variant on the outcome (association 3) is assumed to act solely via the \"intermediate factor\" (association 1). Any alternate pathway due to pleiotropy (denoted here by the dotted line) threatens this core assumption of the Mendelian randomization design.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_26_2467=[""].join("\n");
var outline_f2_26_2467=null;
var title_f2_26_2468="Normal uterine position";
var content_f2_26_2468=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F57272&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F57272&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 471px\">",
"   <div class=\"ttl\">",
"    Normal gravid uterus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 451px; height: 550px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_26_2468=[""].join("\n");
var outline_f2_26_2468=null;
var title_f2_26_2469="Baylisascariasis biopsy";
var content_f2_26_2469=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F79639&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F79639&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 567px\">",
"   <div class=\"ttl\">",
"    Baylisascariasis biopsy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 547px; height: 276px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Cross-sections of larvae of",
"    <em>",
"     B. columnaris",
"    </em>",
"    (a skunk parasite) in the brain of a laboratory-infected mouse. The larval morphology and microscopic manifestations would be similar with",
"    <em>",
"     B. procyonis",
"    </em>",
"    in human tissue. Image taken at 400x magnification.",
"    <br>",
"     (B) Higher magnification (1000x oil) of a cross-section of",
"     <em>",
"      B. columnaris",
"     </em>",
"     from the same specimen as figure A. Notice the prominent alae (green arrows), excretory columns (red arrows), and multinucleate intestinal cells (blue arrow).",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced from: Centers for Disease Control and Prevention. Parasites and Health: Baylisascariasis. Available at:",
"      <a href=\"file://dpd.cdc.gov/dpdx/html/Baylisascariasis.htm\" target=\"_blank\">",
"       file://dpd.cdc.gov/dpdx/html/Baylisascariasis.htm",
"      </a>",
"      .",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_26_2469=[""].join("\n");
var outline_f2_26_2469=null;
var title_f2_26_2470="Gifted writing sample 3";
var content_f2_26_2470=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F83649&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F83649&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Writing sample of gifted child during kindergarten",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 392px; height: 509px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fractions mean a part of something. An example is half a pizza or a quarter of a pie.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_26_2470=[""].join("\n");
var outline_f2_26_2470=null;
var title_f2_26_2471="Hydroxychloroquine: Drug information";
var content_f2_26_2471=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Hydroxychloroquine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?17/39/18037?source=see_link\">",
"    see \"Hydroxychloroquine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/0/40965?source=see_link\">",
"    see \"Hydroxychloroquine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F180857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Plaquenil&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F180858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Hydroxyquine&reg;;",
"     </li>",
"     <li>",
"      Gen-Hydroxychloroquine;",
"     </li>",
"     <li>",
"      Mylan-Hydroxychloroquine;",
"     </li>",
"     <li>",
"      Plaquenil&reg;;",
"     </li>",
"     <li>",
"      PRO-Hydroxyquine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F180895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Aminoquinoline (Antimalarial)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F180861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Hydroxychloroquine sulfate 200 mg is equivalent to 155 mg hydroxychloroquine base and 250 mg chloroquine phosphate. All doses below expressed as hydroxychloroquine sulfate. Second-line alternative treatment for malaria (chloroquine is preferred).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Malaria, chemoprophylaxis:",
"     </b>",
"     Oral: 400 mg weekly on same day each week; begin 2 weeks before exposure; continue for 4 weeks (per CDC guidelines) after leaving endemic area; if suppressive therapy is not begun prior to the exposure, double the initial dose and give in 2 doses, 6 hours apart and continue treatment for 8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Malaria, acute attack:",
"     </b>",
"     Oral: 800 mg initially, followed by 400 mg at 6, 24, and 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Rheumatoid arthritis:",
"     </b>",
"     Oral: Initial: 400-600 mg/day taken with food or milk; increase dose gradually until optimum response level is reached; usually after 4-12 weeks dose should be reduced by",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     to a maintenance dose of 200-400 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lupus erythematosus:",
"     </b>",
"     Oral: 400 mg every day or twice daily for several weeks-months depending on response; 200-400 mg/day for prolonged maintenance therapy",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F180880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/0/40965?source=see_link\">",
"      see \"Hydroxychloroquine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Hydroxychloroquine sulfate 200 mg is equivalent to 155 mg hydroxychloroquine base and 250 mg chloroquine phosphate. All doses below expressed as hydroxychloroquine sulfate. Second-line alternative treatment for malaria (chloroquine is preferred).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Malaria, chemoprophylaxis:",
"     </b>",
"     Oral: 6.5 mg/kg once weekly (not to exceed 400 mg/dose); begin 2 weeks before exposure; continue for 4 weeks (per CDC guidelines) after leaving endemic area; if suppressive therapy is not begun prior to the exposure, double the initial dose and give in 2 doses, 6 hours apart and continue treatment for 8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Malaria, acute attack:",
"     </b>",
"     Oral: 13 mg/kg initially (not to exceed 800 mg/dose), followed by 6.5 mg/kg (not to exceed 400 mg/dose) at 6, 24, and 48 hours",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F180862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F9792113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution; dosage adjustment may be necessary in severe dysfunction (Bernstein, 1992); specific guidelines not available.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F180863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution; dosage adjustment may be necessary.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F180836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as sulfate: 200 mg [equivalent to 155 mg base]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Plaquenil&reg;: 200 mg [equivalent to 155 mg base]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F180822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F180838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with food or milk.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F180837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Suppression and treatment of acute attacks of malaria; treatment of systemic lupus erythematosus (SLE) and rheumatoid arthritis",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F180892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Porphyria cutanea tarda, polymorphous light eruptions",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F180902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Hydroxychloroquine may be confused with hydrocortisone",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Plaquenil&reg; may be confused with Platinol",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F180893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Cardiomyopathy (rare, relationship to hydroxychloroquine unclear)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Ataxia, dizziness, emotional changes, headache, irritability, lassitude, nervousness, nightmares, psychosis, seizure, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, angioedema, bleaching of hair, pigmentation changes (skin and mucosal; black-blue color), rash (acute generalized exanthematous pustulosis, erythema annulare centrifugum, exfoliative dermatitis, lichenoid, maculopapular, morbilliform, purpuric, Stevens-Johnson syndrome, urticarial), urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramping, anorexia, diarrhea, nausea, vomiting, weight loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, aplastic anemia, hemolysis (in patients with glucose-6-phosphate deficiency), leukopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Abnormal liver function/hepatic failure (isolated cases)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myopathy, palsy, or neuromyopathy leading to progressive weakness and atrophy of proximal muscle groups (may be associated with mild sensory changes, loss of deep tendon reflexes, and abnormal nerve conduction)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Abnormal color vision, abnormal retinal pigmentation, atrophy, attenuation of retinal arterioles, corneal changes/deposits (visual disturbances, blurred vision, photophobia [reversible on discontinuation]), decreased visual acuity, disturbance in accommodation, keratopathy, macular edema, nystagmus, optic disc pallor/atrophy, pigmentary retinopathy, retinopathy (early changes reversible [may progress despite discontinuation if advanced]), scotoma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Deafness, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Exacerbation of porphyria and nonlight sensitive psoriasis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchospasm, respiratory failure (myopathy-related)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F180842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to hydroxychloroquine, 4-aminoquinoline derivatives, or any component of the formulation; retinal or visual field changes attributable to 4-aminoquinolines; long-term use in children",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F180826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular: Rare cardiomyopathy has been associated with long-term use of hydroxychloroquine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic: Aminoquinolines have been associated with rare hematologic reactions, including agranulocytosis, aplastic anemia, and thrombocytopenia; monitoring (CBC) is recommended in prolonged therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuromuscular: Myopathy, neuromyopathy, and progressive weakness have been associated with aminoquinoline derivatives; muscle strength (especially proximal muscles) should be assessed periodically during prolonged therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ophthalmic effects: Hydroxychloroquine has been associated with important adverse effects on vision, including loss of visual acuity, macular pigmentary changes, and loss of foveal reflex. Risk factors include daily doses &gt;6.5 mg/kg lean body weight. Baseline assessment of renal and hepatic function is recommended (Jones, 1999). Monitoring is recommended in long-term therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; G6PD deficiency: Use with caution in patients with known G6PD; use of 4-aminoquinolines such as chloroquine has been associated with hemolysis and renal impairment  in this population.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment, alcoholism, or concurrent therapy with hepatotoxic agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Porphyria: Use with caution in patients with porphyria; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psoriasis: Use with caution in patients with psoriasis; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics:  Use caution due to increased sensitivity to aminoquinolones; long-term use in children is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Malaria: Hydroxychloroquine is not effective against chloroquine-resistant strains of",
"     <i>",
"      P. falciparum",
"     </i>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician:",
"     <b>",
"      [U.S. Boxed Warning]: Should be prescribed by physicians familiar with its use.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F180831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anthelmintics: Aminoquinolines (Antimalarial) may decrease the serum concentration of Anthelmintics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): Antimalarial Agents may increase the serum concentration of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Artemether: May enhance the adverse/toxic effect of Antimalarial Agents. Management: Artemether/Lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Aminoquinolines (Antimalarial) may decrease the metabolism of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Atenolol; Carteolol (Ophthalmic); Levobunolol; Metipranolol; Nadolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Aminoquinolines (Antimalarial) may increase the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dapsone (Systemic): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Systemic). Specifically, concomitant use of antimalarial agents with dapsone may increase the risk of hemolytic reactions. Dapsone (Systemic) may enhance the adverse/toxic effect of Antimalarial Agents. Specifically, concomitant use of dapsone with antimalarial agents may increase the risk for hemolytic reactions.  Management: Closely monitor patients for signs/symptoms of hemolytic reactions with concomitant use of dapsone and antimalarial agents, particularly in patients deficient in glucose-6-phosphate dehydrogenase (G6PD), methemoglobin reductase, or with hemoglobin M.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dapsone (Topical): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Topical). Specifically, the risk of hemolytic reactions may be increased.  Management: Closely monitor for signs/symptoms of hemolytic reactions with concomitant use of topical dapsone and antimalarial agents. Patients with glucose-6-phosphate dehydrogenase deficiency may be at particularly high risk for adverse hematologic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lumefantrine: Antimalarial Agents may enhance the adverse/toxic effect of Lumefantrine.  Management: Artemether/Lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mefloquine: Aminoquinolines (Antimalarial) may enhance the adverse/toxic effect of Mefloquine. Specifically, the risk for QTc-prolongation and the risk for convulsions may be increased. Mefloquine may increase the serum concentration of Aminoquinolines (Antimalarial).  Management: Avoid concurrent use, and delay administration of mefloquine until at least 12 hours after the last dose of an aminoquinoline antimalarial when possible.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Hydroxychloroquine may enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F180854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Avoid ethanol (due to GI irritation).",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5265901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Malaria infection in pregnant women may be more severe than in nonpregnant women. Therefore, pregnant women and women who are likely to become pregnant are advised to avoid travel to malaria-risk areas. Hydroxychloroquine is recommended as an alternative treatment of pregnant women for uncomplicated malaria in chloroquine-sensitive regions. Women exposed to hydroxychloroquine for the  treatment of rheumatoid arthritis or systemic lupus erythematosus during pregnancy may be enrolled in the Organization of Teratology Information Specialists (OTIS) Autoimmune Diseases Study pregnancy registry (877-311-8972).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F180867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk (AAP considers &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F180845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with food or milk.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F180844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Hydroxychloroquine Sulfate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (100): $110.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Plaquenil Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (100): $405.38",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F180834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC at baseline and periodically; liver function. Ophthalmologic exam at baseline and every 3 months during prolonged therapy (including visual acuity, slit-lamp, fundoscopic, and visual field exam); muscle strength (especially proximal, as a symptom of neuromyopathy) during long-term therapy",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F180846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Chloguin (TW);",
"     </li>",
"     <li>",
"      Dimard (CO, EC);",
"     </li>",
"     <li>",
"      Dolquine (ES);",
"     </li>",
"     <li>",
"      Ercoquin (DK, NO);",
"     </li>",
"     <li>",
"      Evoquin (AR, UY);",
"     </li>",
"     <li>",
"      Fen Le (CL);",
"     </li>",
"     <li>",
"      Geniquin (TW);",
"     </li>",
"     <li>",
"      Haloxin (SG);",
"     </li>",
"     <li>",
"      HCQS (PE, TH);",
"     </li>",
"     <li>",
"      Hydroquin (TH);",
"     </li>",
"     <li>",
"      Hydroquine (TW);",
"     </li>",
"     <li>",
"      Oxiklorin (FI, KP);",
"     </li>",
"     <li>",
"      Plaquenil (LU, MX);",
"     </li>",
"     <li>",
"      Plaquenil Sulfate (AR, AT, AU, BB, BE, BF, BG, BJ, BM, BS, BZ, CH, CI, CL, CZ, DK, EE, ES, ET, FI, FR, GB, GH, GM, GN, GR, GY, HK, HN, IE, IL, IT, JM, KE, LR, MA, ML, MR, MT, MU, MW, MY, NE, NG, NL, NO, NZ, PH, RU, SC, SD, SE, SK, SL, SN, SR, TH, TN, TR, TT, TW, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Plaquinol (BR, CN, CO, CR, DO, GT, HN, NI, PA, PE, PT, PY, SV, VE);",
"     </li>",
"     <li>",
"      Quensyl (DE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F180825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Interferes with digestive vacuole function within sensitive malarial parasites by increasing the pH and interfering with lysosomal degradation of hemoglobin; inhibits locomotion of neutrophils and chemotaxis of eosinophils; impairs complement-dependent antigen-antibody reactions",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F180841\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Rheumatic disease: May require 4-6 weeks to respond",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid and complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 55%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic; metabolites include desethylhydroxychloroquine and desethylchloroquine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 32-50 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Rheumatic disease: Several months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (as metabolites and unchanged drug [up to 60%]); may be enhanced by urinary acidification",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, &ldquo;Transfer of Drugs and Other Chemicals Into Human Breast Milk,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108:776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/26/2471/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bernstein HN, &ldquo;Ocular Safety of Hydroxychloroquine (Plaquenil),&rdquo;",
"      <i>",
"       South Med J",
"      </i>",
"      ,  1992, 85(3):274-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/26/2471/abstract-text/1546352/pubmed\" id=\"1546352\" target=\"_blank\">",
"        1546352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Buchanan NM, Toubi E, Khamashta MA, et al, &ldquo;The Safety of Hydroxychloroquine in Lupus Pregnancy: Experience in 27 Pregnancies,&rdquo;",
"      <i>",
"       Br J Rheumatol",
"      </i>",
"      , 1995, 34(Suppl 1):14.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Guidelines for the Treatment of Malaria in the United States.&rdquo; Available at",
"      <a href=\"file://www.cdc.gov/malaria/diagnosis_treatment/index.html\" target=\"_blank\">",
"       file://www.cdc.gov/malaria/diagnosis_treatment/index.html",
"      </a>",
"      and",
"      <a href=\"file://www.cdc.gov/malaria/pdf/treatmenttable.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/malaria/pdf/treatmenttable.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Drugs for Parasitic Infections,&rdquo;",
"      <i>",
"       Med Lett Drugs Ther",
"      </i>",
"      , 1993, 35(911):111-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/26/2471/abstract-text/8246830/pubmed\" id=\"8246830\" target=\"_blank\">",
"        8246830",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Emery H, &ldquo;Clinical Aspects of Systemic Lupus Erythematosus in Childhood,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1986, 33(5):1177-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/26/2471/abstract-text/3763254/pubmed\" id=\"3763254\" target=\"_blank\">",
"        3763254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Furst DE, &ldquo;Rational Use of Disease-Modifying Antirheumatic Drugs,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1990, 39(1):19-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/26/2471/abstract-text/2178910/pubmed\" id=\"2178910\" target=\"_blank\">",
"        2178910",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Giannini EH and Cawkwell GD, &ldquo;Drug Treatment in Children With Juvenile Rheumatoid Arthritis. Past, Present, and Future,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1995, 42(5):1099-125.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/26/2471/abstract-text/7567188/pubmed\" id=\"7567188\" target=\"_blank\">",
"        7567188",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gould FK, Denning DW, Elliott TS, et al, &ldquo;Guidelines for the Diagnosis and Antibiotic Treatment of Endocarditis in Adults:  A Report of the Working Party of the British Society for Antimicrobial Chemotherapy,&rdquo;",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 2012, 67(2):269-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/26/2471/abstract-text/22086858/pubmed\" id=\"22086858\" target=\"_blank\">",
"        22086858",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Guidelines for the Management of Rheumatoid Arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines,&rdquo;",
"      <i>",
"       Arthritis Rheum",
"      </i>",
"      , 1996, 39(5):713-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/26/2471/abstract-text/8639167/pubmed\" id=\"8639167\" target=\"_blank\">",
"        8639167",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hart LE and Tugwell P, &ldquo;The Use of Disease-Modifying Antirheumatic Drugs in the Management of Rheumatoid Arthritis,&rdquo;",
"      <i>",
"       Postgrad Med J",
"      </i>",
"      , 1989, 65(770):905-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/26/2471/abstract-text/2694146/pubmed\" id=\"2694146\" target=\"_blank\">",
"        2694146",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jones SK, &ldquo;Ocular Toxicity and Hydroxychloroquine: Guidelines for Screening,&rdquo;",
"      <i>",
"       Br J Derm",
"      </i>",
"      , 1999, 140(1):3-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/26/2471/abstract-text/10215761/pubmed\" id=\"10215761\" target=\"_blank\">",
"        10215761",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kutz DC and Bridges AJ, &ldquo;Bullous Rash and Brown Urine in a Systemic Lupus Erythematosus Patient Treated With Hydroxychloroquine,&rdquo;",
"      <i>",
"       Arthritis Rheum",
"      </i>",
"      , 1995, 38(3):440-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/26/2471/abstract-text/7880200/pubmed\" id=\"7880200\" target=\"_blank\">",
"        7880200",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levy M, Buskila D, Gladman DD, et al, &ldquo;Pregnancy Outcome Following First Trimester Exposure to Chloroquine,&rdquo;",
"      <i>",
"       Am J Perinatol",
"      </i>",
"      , 1991, 8(3):174-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/26/2471/abstract-text/2029276/pubmed\" id=\"2029276\" target=\"_blank\">",
"        2029276",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ostensen M, Brown ND, Chiang PK, et al, \"Hydroxychloroquine in Human Breast Milk,\"",
"      <i>",
"       Eur J Clin Pharmacol",
"      </i>",
"      , 1985, 28(3):357.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/26/2471/abstract-text/4007043/pubmed\" id=\"4007043\" target=\"_blank\">",
"        4007043",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Panisko DM and Keystone JS, &ldquo;Treatment of Malaria - 1990,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1990, 39(2):160-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/26/2471/abstract-text/2183998/pubmed\" id=\"2183998\" target=\"_blank\">",
"        2183998",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Seguin P, Camus C, Leroy JP, et al, &ldquo;Respiratory Failure Associated With Hydroxychloroquine Neuromyopathy,&rdquo;",
"      <i>",
"       Eur Neurol",
"      </i>",
"      , 1995, 35(4):236-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/26/2471/abstract-text/7671986/pubmed\" id=\"7671986\" target=\"_blank\">",
"        7671986",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Singh JA, Furst DE, Bharat A, et al, &ldquo;2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis,&rdquo;",
"      <i>",
"       Arthritis Care Res (Hoboken)",
"      </i>",
"      , 2012, 64(5):625-39.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/26/2471/abstract-text/22473917/pubmed\" id=\"22473917\" target=\"_blank\">",
"        22473917",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tett SE, Cutler DJ, Day RO, et al, &ldquo;Bioavailability of Hydroxychloroquine Tablets in Healthy Volunteers,&rdquo;",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 1989, 27(6):771-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/26/2471/abstract-text/2757893/pubmed\" id=\"2757893\" target=\"_blank\">",
"        2757893",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wang R, &ldquo;Hydroxychloroquine Cardiotoxicity,&rdquo;",
"      <i>",
"       Clin Toxicol",
"      </i>",
"      , 1995, 33(5):548.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      White NJ, &ldquo;The Treatment of Malaria,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1996, 335(11):800-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/26/2471/abstract-text/8703186/pubmed\" id=\"8703186\" target=\"_blank\">",
"        8703186",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8541 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-484BBBCA60-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_26_2471=[""].join("\n");
var outline_f2_26_2471=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708908\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180857\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180858\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180895\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180861\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180880\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180862\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9792113\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180863\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180836\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180822\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180838\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180837\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180892\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180902\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180893\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180842\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180826\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299491\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180831\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180854\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5265901\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180867\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180845\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180844\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180834\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180846\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180825\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180841\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8541\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8541|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/39/18037?source=related_link\">",
"      Hydroxychloroquine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/0/40965?source=related_link\">",
"      Hydroxychloroquine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_26_2472="Rosiglitazone: Drug information";
var content_f2_26_2472=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Rosiglitazone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?0/50/806?source=see_link\">",
"    see \"Rosiglitazone: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/35/13879?source=see_link\">",
"    see \"Rosiglitazone: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F219381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Avandia&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F219382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Avandia&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F219410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidiabetic Agent, Thiazolidinedione",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F219385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Type 2 diabetes:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     All patients should be initiated at the lowest recommended dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Monotherapy: Initial: 4 mg daily as a single daily dose or in divided doses twice daily. If response is inadequate after 8-12 weeks of treatment, the dosage may be increased to 8 mg daily as a single daily dose or in divided doses twice daily. In clinical trials, the 4 mg twice-daily regimen resulted in the greatest reduction in fasting plasma glucose and Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Combination therapy: When adding rosiglitazone to existing therapy, continue current dose(s) of previous agents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"     With sulfonylureas or metformin (or sulfonylurea plus metformin): Initial: 4 mg daily as a single daily dose or in divided doses twice daily. If response is inadequate after 8-12 weeks of treatment, the dosage may be increased to 8 mg daily as a single daily dose or in divided doses twice daily. Reduce dose of sulfonylurea if hypoglycemia occurs. It is unlikely that the dose of metformin will need to be reduced due to hypoglycemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     With metformin: Initial: 4 mg daily as a single daily dose or in divided doses twice daily. If response is inadequate after 8-12 weeks of treatment, the dosage may be increased to 8 mg daily as a single daily dose or in divided doses twice daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     With a sulfonylurea: 4 mg daily as a single daily dose or in divided doses twice daily. Dose should not exceed 4 mg daily when using in combination with a sulfonylurea. Reduce dose of sulfonylurea if hypoglycemia occurs.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F219386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F219387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adjustment is necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F219388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Clearance is significantly lower in hepatic impairment. Therapy should not be initiated if the patient exhibits active liver disease or increased transaminases (ALT &gt;2.5 times the upper limit of normal) at baseline.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F219357\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Avandia&reg;: 2 mg, 4 mg, 8 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F219342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11245565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As a requirement of the REMS program, the prescribing and dispensing of any rosiglitazone-containing medication in the U.S. requires physician and patient enrollment in the Avandia-Rosiglitazone Medicines Access Program&trade;. Complete program details are available at www.avandia.com or by calling the program Coordinating Center at 800-282-6342.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Health Canada requires written informed consent for new and current patients receiving rosiglitazone.",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm085922.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm085922.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9613923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F219358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Type 2 diabetes mellitus (noninsulin dependent, NIDDM):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Monotherapy: Improve glycemic control as an adjunct to diet and exercise",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Canadian labeling approves use as monotherapy only when metformin is contraindicated or not tolerated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Combination therapy:",
"     <b>",
"      Note:",
"     </b>",
"     Use when diet, exercise, and a single agent do not result in adequate glycemic control.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     U.S. labeling: In combination with a sulfonylurea, metformin, or sulfonylurea plus metformin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Canadian labeling: In combination with metformin; in combination with a sulfonylurea only when metformin use is contraindicated or not tolerated",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F219417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Avandia&reg; may be confused with Avalide&reg;, Coumadin&reg;, Prandin&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Avandia [U.S., Canada, and multiple international markets] may be confused with Avanza brand name for mirtazapine [Australia]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F219408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     The rate of certain adverse reactions (eg, anemia, edema, hypoglycemia) may be higher with some combination therapies.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%: Endocrine &amp; metabolic: HDL-cholesterol increased, LDL-cholesterol increased, total cholesterol increased, weight gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema (5%), hypertension (4%); heart failure/CHF (up to 2% to 3% in patients receiving insulin; incidence likely higher in patients with pre-existing HF; myocardial ischemia (3%; incidence likely higher in patients with preexisting CAD)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypoglycemia (1% to 3%; combination therapy with insulin: 12% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Fractures (up to 9%; incidence greater in females; usually upper arm, hand, or foot), arthralgia (5%), back pain (4% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Upper respiratory tract infection (4% to 10%), nasopharyngitis (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Injury (8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylaxis, angina, angioedema, bilirubin increased, blurred vision, cardiac arrest, dyspnea, coronary artery disease, coronary thrombosis, hematocrit decreased, hemoglobin decreased, hepatic failure, hepatitis, HDL-cholesterol decreased, jaundice (reversible), macular edema, MI, pleural effusion, pruritus, pulmonary edema, rash, Stevens-Johnson syndrome, thrombocytopenia, transaminases increased, urticaria, visual acuity decreased, weight gain (rapid, excessive; usually due to fluid accumulation), WBC count decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Rare cases of hepatocellular injury have been reported in men in their 60s within 2-3 weeks after initiation of rosiglitazone therapy. LFTs in these patients revealed severe hepatocellular injury which responded with rapid improvement of liver function and resolution of symptoms upon discontinuation of rosiglitazone. Patients were also receiving other potentially hepatotoxic medications (Al-Salman, 2000; Freid, 2000).",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F219361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     NYHA Class III/IV heart failure (initiation of therapy)",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling: Hypersensitivity to rosiglitazone or any component of the formulation; any stage of heart failure (eg, NYHA Class I, II, III, IV); serious hepatic impairment; pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F219346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fractures: Increased incidence of bone fractures in females treated with rosiglitazone observed during analysis of long-term trial; majority of fractures occurred in the upper arm, hand and foot (differing from the hip or spine fractures usually associated with postmenopausal osteoporosis). Consider risk of fracture prior to initiation and during use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure/cardiac effects:",
"     <b>",
"      [U.S. Boxed Warning]: Thiazolidinediones, including rosiglitazone, may cause or exacerbate congestive heart failure;",
"     </b>",
"     closely monitor for signs and symptoms of congestive heart failure (eg, rapid weight gain, dyspnea, edema), particularly after initiation or dose increases. Not recommended for use in any patient with symptomatic heart failure. In the U.S., initiation of therapy is contraindicated in patients with NYHA class III or IV heart failure; in Canada, use is contraindicated in patients with any stage of heart failure (NYHA I, II, III, IV). Use with caution in patients with edema; may increase plasma volume and/or cause fluid retention. A higher frequency of cardiovascular events has been noted in patients with NYHA class I or II heart failure treated with rosiglitazone. Use may also be associated with an increased risk of angina and MI. Use with caution in patients at risk for cardiovascular events and monitor closely. Discontinue if any deterioration in cardiac status occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic effects: May decrease hemoglobin, hematocrit, and/or WBC count (slight); effects may be related to increased plasma volume and/or dose-related.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Weight gain: Dose-related weight gain observed with use; mechanism unknown but likely associated with fluid retention and fat accumulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anemia: Use with caution in patients with anemia; may reduce hemoglobin and hematocrit.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes, type 1: Mechanism requires the presence of insulin; therefore, use in type 1 diabetes (insulin dependent, IDDM) or diabetic ketoacidosis is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with elevated transaminases (AST or ALT); do not initiate in patients with active liver disease or ALT &gt;2.5 times the upper limit of normal (ULN) at baseline; evaluate patients with ALT &le;2.5 times ULN at baseline or during therapy for cause of enzyme elevation; during therapy, if ALT &gt;3 times ULN, reevaluate levels promptly and discontinue if elevation persists or if jaundice occurs at any time during use. Idiosyncratic hepatotoxicity has been reported with another thiazolidinedione agent (troglitazone); avoid use in patients who previously experienced jaundice during troglitazone therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ischemic heart disease: Do not initiate in patients with stable ischemic heart disease due to an increased risk of cardiovascular complications (Fihn , 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Macular edema/diabetic retinopathy: Use with caution in patients with pre-existing macular edema or diabetic retinopathy; postmarketing events of new-onset or worsening diabetic macular edema with decreased visual acuity have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypoglycemic agents: Combination therapy with other hypoglycemic agents may increase risk for hypoglycemic events; dose reduction with the concomitant agent may be warranted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Insulin: Avoid use of rosiglitazone with insulin due to an increased risk of edema, congestive heart failure, and myocardial ischemic events.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Nitrates: Concomitant use of rosiglitazone with nitrates is not recommended. An increased risk of myocardial ischemia has been observed in nitrate users versus non-nitrate users in clinical studies.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Metformin/sulfonylureas (Canadian labeling; not in U.S. labeling): Rosiglitazone may be added to metformin or a sulfonylurea (if metformin is contraindicated or not tolerated) if glycemic control is inadequate. The use of triple therapy (rosiglitazone in combination with metformin and a sulfonylurea) is not indicated due to increased risks of congestive heart failure and fluid retention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Premenopausal/anovulatory females: Use with caution in premenopausal, anovulatory women; may result in a resumption of ovulation, increasing the risk of pregnancy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; REMS program:",
"     <b>",
"      [U.S. Boxed Warning]: Due to cardiovascular risks, rosiglitazone-containing medications are only available through the Avandia-Rosiglitazone Medicines Access Program&trade;.",
"     </b>",
"     Patients and prescribers must be registered with and meet conditions of the program. Call 1-800-282-6342 or visit www.avandia.com for more information.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F219404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C8 (major), CYP2C9 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C19 (weak), CYP2C8 (moderate), CYP2C9 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F219351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Antidiabetic Agents (Thiazolidinedione).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Inducers (Strong): May increase the metabolism of CYP2C8 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Inhibitors (Moderate): May decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Inhibitors (Strong): May decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Substrates: CYP2C8 Inhibitors (Moderate) may decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP2C8 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gemfibrozil: May decrease the metabolism of Antidiabetic Agents (Thiazolidinedione). Management: Limit pioglitazone maximum adult dose to 15 mg/day, and consider dose reduction of rosiglitazone, when used in combination with gemfibrozil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: May enhance the adverse/toxic effect of other Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Insulin: May enhance the fluid-retaining effect of Antidiabetic Agents (Thiazolidinedione).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Luteinizing Hormone-Releasing Hormone Analogs: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP2C8 Substrates. Management: Use CYP2C8 substrates at the lowest recommended dose, and monitor closely for adverse effects (including myopathy), during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: May enhance the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pregabalin: May enhance the fluid-retaining effect of Antidiabetic Agents (Thiazolidinedione).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May increase the metabolism of Antidiabetic Agents (Thiazolidinedione).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents. Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: May diminish the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May decrease the metabolism of Antidiabetic Agents (Thiazolidinedione).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vasodilators (Organic Nitrates): May enhance the adverse/toxic effect of Rosiglitazone. Specifically, a greater risk of myocardial ischemia was reported for users of this combination in a meta-analysis. Management: Consider alternatives to this combination when possible.  Rosiglitazone prescribing information states that the combination of rosiglitazone and a nitrate is not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F219377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (may cause hypoglycemia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Peak concentrations are lower by 28% and delayed when administered with food, but these effects are not believed to be clinically significant.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid alfalfa, aloe, bilberry, bitter melon, burdock, celery, damiana, fenugreek, garcinia, garlic, ginger, ginseng (American), gymnema, marshmallow, stinging nettle (may cause hypoglycemia).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F219353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F219364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Rosiglitazone is classified as pregnancy category C due to adverse effects observed in initial animal studies. Rosiglitazone has been found to cross the placenta during the first trimester of pregnancy. Inadvertent use early in pregnancy has not shown adverse fetal effects although in the majority of cases, the medication was stopped as soon as pregnancy was detected. Thiazolidinediones may cause ovulation in anovulatory premenopausal women, increasing the risk of pregnancy; adequate contraception in premenopausal women is recommended. Maternal hyperglycemia can be associated with adverse effects in the fetus, including macrosomia, neonatal hyperglycemia, and hyperbilirubinemia; the risk of congenital malformations is increased when the Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     is above the normal range. Diabetes can also be associated with adverse effects in the mother. Poorly-treated diabetes may cause end-organ damage that may in turn negatively affect obstetric outcomes. Physiologic glucose levels should be maintained prior to and during pregnancy to decrease the risk of adverse events in the mother and the fetus. Until additional safety and efficacy data are obtained, the use of oral agents is generally not recommended as routine management of GDM or type 2 diabetes mellitus during pregnancy. Insulin is the drug of choice for the control of diabetes mellitus during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F219391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F219365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if rosiglitazone is excreted in breast milk. Breast-feeding is not recommended by the manufacturer.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F219366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of type 2 diabetes mellitus (noninsulin dependent, NIDDM) should include diet control. May be taken without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F219363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Avandia Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (60): $189.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (30): $140.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8 mg (30): $255.17",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F219355\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hemoglobin A",
"     <sub>",
"      1c",
"     </sub>",
"     , fasting serum glucose; signs and symptoms of fluid retention or heart failure; liver enzymes (prior to initiation of therapy, then periodically thereafter); ophthalmic exams. Evaluate patients with ALT &le;2.5 times ULN at baseline or during therapy for cause of enzyme elevation. Patients with an elevation in ALT &gt;3 times ULN should be rechecked as soon as possible. If the ALT levels remain &gt;3 times ULN, therapy with rosiglitazone should be discontinued.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F6258750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Recommendations for glycemic control in nonpregnant adults with diabetes (ADA, 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     : &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     goal may be targeted based on patient-specific characteristics)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Preprandial capillary plasma glucose: 70-130 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peak postprandial capillary blood glucose: &lt;180 mg/dL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F219367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Avandia (AR, AT, AU, BB, BE, BG, BM, BO, BR, BS, BZ, CH, CL, CN, CR, CZ, DE, DK, DO, EC, ES, FI, FR, GB, GR, GT, GY, HK, HN, ID, IE, IL, IT, JM, KP, MX, MY, NI, NL, NO, NZ, PA, PH, PK, PL, PR, PT, PY, RU, SE, SG, SR, SV, TH, TR, TT, UY, VE);",
"     </li>",
"     <li>",
"      Diaglinex (PE);",
"     </li>",
"     <li>",
"      Reglit (PE);",
"     </li>",
"     <li>",
"      Rezult (IN);",
"     </li>",
"     <li>",
"      Rosix (CO);",
"     </li>",
"     <li>",
"      Rossini (IL);",
"     </li>",
"     <li>",
"      Vidya (TW);",
"     </li>",
"     <li>",
"      Winsepal (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F219345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Thiazolidinedione antidiabetic agent that lowers blood glucose by improving target cell response to insulin, without increasing pancreatic insulin secretion. It has a mechanism of action that is dependent on the presence of insulin for activity. Rosiglitazone is an agonist for peroxisome proliferator-activated receptor-gamma (PPARgamma). Activation of nuclear PPARgamma receptors influences the production of a number of gene products involved in glucose and lipid metabolism. PPARgamma is abundant in the cells within the renal collecting tubules; fluid retention results from stimulation by thiazolidinediones which increases sodium reabsorption.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F219360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Delayed; Maximum effect: Up to 12 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      dss",
"     </sub>",
"     (apparent): 17.6 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 99.8%; primarily albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic (99%) via CYP2C8; minor metabolism via CYP2C9",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 3-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: 1 hour; delayed with food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~64%) and feces (~23%) as metabolites",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Al-Salman J, Arjomand H, Kemp DG, et al, &ldquo;Hepatocellular Injury in a Patient Receiving Rosiglitazone. A Case Report,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2000, 132(2):121-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/26/2472/abstract-text/10644273/pubmed\" id=\"10644273\" target=\"_blank\">",
"        10644273",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl 1):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/26/2472/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/26/2472/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Belli SH, Graffigna MN, Oneto A, et al, &ldquo;Effect of Rosiglitazone on Insulin Resistance, Growth Factors, and Reproductive Disturbances in Women With Polycystic Ovary Syndrome,&rdquo;",
"      <i>",
"       Fertil Steril",
"      </i>",
"      , 2004, 81(3):624-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/26/2472/abstract-text/15037412/pubmed\" id=\"15037412\" target=\"_blank\">",
"        15037412",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cataldo NA, Abbasi F, McLaughlin TL, et al, &ldquo;Metabolic and Ovarian Effects of Rosiglitazone Treatment for 12 Weeks in Insulin-Resistant Women With Polycystic Ovary Syndrome,&rdquo;",
"      <i>",
"       Hum Reprod",
"      </i>",
"      , 2006, 21(1):109-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/26/2472/abstract-text/16155076/pubmed\" id=\"16155076\" target=\"_blank\">",
"        16155076",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dormandy JA, Charbonnel B, Eckland DJ, et al, &ldquo;Secondary Prevention of Macrovascular Events in Patients With Type 2 Diabetes in the PROactive Study (PROspective PioglitAzone Clinical Trial In MacroVascular Events): A Randomised Controlled Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2005, 366(9493):1279-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/26/2472/abstract-text/16214598/pubmed\" id=\"16214598\" target=\"_blank\">",
"        16214598",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(25):3097-137.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/26/2472/abstract-text/23166211/pubmed\" id=\"23166211\" target=\"_blank\">",
"        23166211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Freid J, Everitt D, and Boscia J, &ldquo;Rosiglitazone and Hepatic Failure,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2000, 132(2):164-6.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gerstein HC, Yusuf S, Bosch J, et al, &ldquo;Effect Of Rosiglitazone On The Frequency Of Diabetes In Patients With Impaired Glucose Tolerance or Impaired Fasting Glucose: A Randomized Controlled Trial. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication)Trial Investigators,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2006,368(9541):2096-105.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/26/2472/abstract-text/16997664/pubmed\" id=\"16997664\" target=\"_blank\">",
"        16997664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gutschi LM, Malcolm JC, Favreau CM, et al, &ldquo;Paradoxically Decreased HDL-Cholesterol Levels Associated With Rosiglitazone Therapy,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2006, 40(9):1672-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/26/2472/abstract-text/16912247/pubmed\" id=\"16912247\" target=\"_blank\">",
"        16912247",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Handelsman Y, Mechanick JI, Blonde L, et al, &ldquo;American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan,&rdquo;",
"      <i>",
"       Endocr Pract",
"      </i>",
"      , 2011, 17(Suppl 2):1-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/26/2472/abstract-text/21474420/pubmed\" id=\"21474420\" target=\"_blank\">",
"        21474420",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Home PD, Pocock SJ, Beck-Nielsen H, et al, &ldquo;Rosiglitazone Evaluated for Cardiovascular Outcomes - An Interim Analysis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007, 357(1):28-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/26/2472/abstract-text/17551159/pubmed\" id=\"17551159\" target=\"_blank\">",
"        17551159",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kahn SE, Haffner SM, Heise MA, et al, &ldquo;Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006:355(23):2427-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/26/2472/abstract-text/17145742/pubmed\" id=\"17145742\" target=\"_blank\">",
"        17145742",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kaul S, Bolger AF, Herrington D, et al, \"Thiazolidinedione Drugs and Cardiovascular Risks: A Science Advisory From the American Heart Association and American College of Cardiology Foundation,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 121(16):1868-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/26/2472/abstract-text/20179252/pubmed\" id=\"20179252\" target=\"_blank\">",
"        20179252",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kirkman M, Briscoe VJ, Clark N, et al, \"Diabetes in Older Adults: A Consensus Report,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012; doi: 10.1111/jgs.12035.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/26/2472/abstract-text/23106132/pubmed\" id=\"23106132\" target=\"_blank\">",
"        23106132",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lago RM, Singh PP, and Nesto RW, &ldquo;Congestive Heart Failure and Cardiovascular Death in Patients With Prediabetes and Type 2 Diabetes Given Thiazolidinediones: A Meta-Analysis of Randomized Clinical Trials,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2007, 370(9593):1129-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/26/2472/abstract-text/17905165/pubmed\" id=\"17905165\" target=\"_blank\">",
"        17905165",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Liu S, Huang T, Sahud MA, &ldquo;Rosiglitazone-Induced Immune Thrombocytopenia,&rdquo;",
"      <i>",
"       Platelets",
"      </i>",
"      , 2006, 17(3):143-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/26/2472/abstract-text/16702039/pubmed\" id=\"16702039\" target=\"_blank\">",
"        16702039",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nissen SE, Wolski K, &ldquo;Effects Of Rosiglitazone On The Risk of Myocardial Infarction and Death From Cardiovascular Causes,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007. Available at  file://content.nejm.org/cgi/content/full/NEJMoa072761",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/26/2472/abstract-text/17517853/pubmed\" id=\"17517853\" target=\"_blank\">",
"        17517853",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Qaseem A, Humphrey LL, Sweet DE, et al,&ldquo;Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2012, 156(3):218-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/26/2472/abstract-text/22312141/pubmed\" id=\"22312141\" target=\"_blank\">",
"        22312141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rodbard HW, Jellinger PS, Davidson JA, et al, &ldquo;Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control,&rdquo;",
"      <i>",
"       Endocr Pract",
"      </i>",
"      , 2009, 15(6):540-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/26/2472/abstract-text/19858063/pubmed\" id=\"19858063\" target=\"_blank\">",
"        19858063",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schwartz AV, Sellmeyer DE, Vittinghoff E, et al, &ldquo;Thiazolidinedione Use and Bone Loss in Older Diabetic Adults,&rdquo;",
"      <i>",
"       J Clin Endocrin Metab",
"      </i>",
"      , 2006, 91(9):3349-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/26/2472/abstract-text/16608888/pubmed\" id=\"16608888\" target=\"_blank\">",
"        16608888",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Singh S, Loke YK, and Furberg CD, &ldquo;Long-Term Risk of Cardiovascular Events With Rosiglitazone,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2007, 298(10):1189-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/26/2472/abstract-text/17848653/pubmed\" id=\"17848653\" target=\"_blank\">",
"        17848653",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yaturu S, Bryant B, Jain SK, &ldquo;Thiazolidinedione Treatment Decreases Bone Mineral Density in Type 2 Diabetic Men,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2007, 30(6):1574-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/26/2472/abstract-text/17363747/pubmed\" id=\"17363747\" target=\"_blank\">",
"        17363747",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10249 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-D60132E406-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_26_2472=[""].join("\n");
var outline_f2_26_2472=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709405\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219381\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219382\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219410\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219385\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219386\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219387\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219388\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219357\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219342\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11245565\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874828\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9613923\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219358\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219417\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219408\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219361\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219346\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219404\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219351\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219377\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219353\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219364\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219391\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219365\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219366\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219363\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219355\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6258750\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219367\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219345\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219360\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10249\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10249|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/50/806?source=related_link\">",
"      Rosiglitazone: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/35/13879?source=related_link\">",
"      Rosiglitazone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_26_2473="Psoriasis plaque";
var content_f2_26_2473=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F54581%7EDERM%2F78531&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F54581%7EDERM%2F78531&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Plaque",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An erythematous plaque with coarse scale is present on the knee of this patient with psoriasis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Inverse psoriasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 278px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A well-defined erythematous plaque is present in the inframammary area.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_26_2473=[""].join("\n");
var outline_f2_26_2473=null;
var title_f2_26_2474="Chronic intestinal pseudo-obstruction";
var content_f2_26_2474=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chronic intestinal pseudo-obstruction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/26/2474/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/26/2474/contributors\">",
"     Michael Camilleri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/26/2474/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/26/2474/contributors\">",
"     Lawrence S Friedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/26/2474/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/26/2474/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/26/2474/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pseudo-obstruction is a syndrome characterized by signs and symptoms of a mechanical obstruction of the small or large bowel in the absence of an anatomic lesion that obstructs the flow of intestinal contents. Pseudo-obstruction may be acute or chronic and is characterized by the presence of dilation of the bowel on imaging.",
"   </p>",
"   <p>",
"    This topic review will discuss the etiology, clinical manifestations, diagnosis, and treatment of chronic intestinal pseudo-obstruction. Acute pseudo-obstruction, chronic intestinal dysmotility, and slow transit",
"    <span class=\"nowrap\">",
"     constipation/colon",
"    </span>",
"    inertia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/50/22311?source=see_link\">",
"     \"Acute colonic pseudo-obstruction (Ogilvie's syndrome)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/22/13673?source=see_link\">",
"     \"Etiology and evaluation of chronic constipation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic intestinal pseudo-obstruction (CIPO) is a rare disorder that may be due to an underlying neuropathic disorder (involving the enteric nervous system or extrinsic nervous system), a myopathic disorder (involving the smooth muscle), or abnormality in the interstitial cell of Cajal (ICC) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/26/2474/abstract/1\">",
"     1",
"    </a>",
"    ]. Therefore, there are parallels in the pathobiological mechanisms of CIPO and gastroparesis. &nbsp;",
"   </p>",
"   <p>",
"    Neuropathic, myopathic, or ICC abnormalities may be idiopathic or secondary to another disease. Approximately half of the cases of CIPO are secondary to neurologic, paraneoplastic, autoimmune,",
"    <span class=\"nowrap\">",
"     metabolic/endocrine,",
"    </span>",
"    and infectious diseases.",
"   </p>",
"   <p>",
"    More than one of the element of the neuromuscular apparatus of the gut may be affected in certain diseases. For example, there is an intrinsic neuropathic phase of scleroderma, before the smooth muscle involvement results in myopathy. Similarly, mitochondrial cytopathy results in neuropathy and eventually myopathy. Moreover, diabetes affects extrinsic nerves through autonomic neuropathy, and the ICCs and amyloidosis causes an extrinsic neuropathy followed by myopathic CIPO.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Degenerative neuropathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurologic (eg, Parkinson&rsquo;s disease and Shy-Drager syndrome) and metabolic disorders (eg, diabetes mellitus) can affect the extrinsic nerve pathways supplying the gut. Degenerative neuropathies may result from several putative pathogenetic mechanisms, including altered calcium signaling, mitochondrial dysfunction, and production of free radicals, leading to degeneration and loss of gut intrinsic neurons [",
"    <a class=\"abstract\" href=\"UTD.htm?2/26/2474/abstract/2\">",
"     2",
"    </a>",
"    ]. Neuropathic disorders may be complicated by a myopathic stage when the muscle layer is infiltrated, as in amyloidosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Paraneoplastic immune-mediated pseudo-obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;CIPO has been reported in association with small cell lung cancers or carcinoid tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?2/26/2474/abstract/3\">",
"     3",
"    </a>",
"    ]. These patients often have antineuronal nuclear (anti-Hu) antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?2/26/2474/abstract/4\">",
"     4",
"    </a>",
"    ]. The antibody is postulated to be directed toward an epitope that is shared between the neuronal elements within the enteric nervous system and the underlying malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/26/2474/abstract/5\">",
"     5",
"    </a>",
"    ]. Paraneoplastic syndromes may evoke an",
"    <span class=\"nowrap\">",
"     inflammatory/immune",
"    </span>",
"    infiltrate targeting neurons located in both submucosal and myenteric ganglia of the enteric nervous system (ENS); the cellular infiltrate along with circulating antineuronal antibodies is thought to damage the enteric reflexes thereby contributing to paraneoplastic dysmotility. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40968?source=see_link\">",
"     \"Overview of paraneoplastic syndromes of the nervous system\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37304?source=see_link\">",
"     \"Paraneoplastic syndromes affecting peripheral nerve and muscle\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Immune-mediated pseudo-obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immune-mediated pseudo-obstruction associated with neuronal or smooth muscle involvement has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?2/26/2474/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Scleroderma, dermatomyositis, and systemic lupus erythematosus can alter the enteric nerves, the smooth muscle cells, and possibly the ICC.",
"   </p>",
"   <p>",
"    In one case report, CIPO resulted from the development of antibodies to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/10/17573?source=see_link\">",
"     buserelin",
"    </a>",
"    , an analogue of gonadotropin-releasing hormone (GNRH), leading to the immune mediated destruction of myenteric neurons [",
"    <a class=\"abstract\" href=\"UTD.htm?2/26/2474/abstract/8\">",
"     8",
"    </a>",
"    ]. A small proportion of patients with inflammatory enteric neuropathy have antibodies directed towards neuronal ion channels (voltage-gated potassium channels and neuronal alpha3-AChR) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/26/2474/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Infectious",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chagas disease is the most common infectious cause of CIPO. It is endemic to certain countries, such as Brazil, and is infrequently encountered in patients in the United States unless they have lived for extended periods in South America.",
"   </p>",
"   <p>",
"    Viruses may cause morphologic (ie, inflammatory) or functional changes of the enteric nervous system and extrinsic neural pathways supplying the gut and are detectable in a subset of patients with CIPO.",
"   </p>",
"   <p>",
"    A potential role of a chronic JC virus infection has been suggested in observational studies. In one case-control study comparing specimens from 10 patients with CIPO with 61 control specimens, JC virus proteins (TAg and VP1) were identified in glial cells of the myenteric plexus in 7 out of 10 adult patients with idiopathic CIPO and in none of the control specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?2/26/2474/abstract/10\">",
"     10",
"    </a>",
"    ]. TAg and VP1 were selectively expressed in the myenteric plexuses, indicating an active lytic infection, which would be expected to destroy the host cell. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/44/1734?source=see_link\">",
"     \"Epidemiology of JC and BK virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Radiotherapy and chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;CIPO has been described in association with radiotherapy and chemotherapy for gynecological cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?2/26/2474/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10337704\">",
"    <span class=\"h2\">",
"     Genetic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although most cases of CIPO are sporadic, rare familial cases have been described suggesting an underlying genetic basis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/26/2474/abstract/12\">",
"     12",
"    </a>",
"    ]. A very localized form of genetic neuromuscular denervation or aganglionosis is Hirschsprung disease, which is associated with secondary dilatation proximal to the affected segment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41848?source=see_link\">",
"     \"Congenital aganglionic megacolon (Hirschsprung disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Genetic mutations have been described in animal models of congenital pseudo-obstruction and in rare human syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?2/26/2474/abstract/13\">",
"     13",
"    </a>",
"    ]. One such syndrome associated with CIPO is Waardenburg-Shah syndrome (deafness and pigmentary abnormalities in association with aganglionic megacolon), in which mutations in neural crest-derived cells have been identified in some kindreds [",
"    <a class=\"abstract\" href=\"UTD.htm?2/26/2474/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several additional syndromic forms of CIPO have been described in association with the following genes [",
"    <a class=\"abstract\" href=\"UTD.htm?2/26/2474/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transcription factor SOX10 on chromosome 22 (22p12)",
"     </li>",
"     <li>",
"      DNA polymerase gamma gene (POLG) on chromosome 21 (21q17)",
"     </li>",
"     <li>",
"      Locus on chromosome 8",
"     </li>",
"     <li>",
"      Mutations in filamin A gene (FLNA) and L1 cell adhesion molecule (L1CAM), which causes X-linked inherited CIPO",
"     </li>",
"     <li>",
"      Mutations of the thymidine phosphorylase gene (TP or endothelial cell growth factor-1, ECGF1), which causes familial mitochondrial neurogastrointestinal encephalomyopathy (MNGIE)",
"     </li>",
"     <li>",
"      Expression of phosphatase and tensin homolog deleted on chromosome 10 (Pten, a phosphatase critical for controlling cell growth, proliferation, cell death and ENS development), reduced in the giant ganglia of patients with intestinal neuronal dysplasia and from the aganglionic region of Hirschsprung disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4427919\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal pain, bloating, and distension are the most common clinical features of chronic intestinal pseudo-obstruction (CIPO). These symptoms may be acute, recurrent, or chronic.",
"   </p>",
"   <p>",
"    The most common features at diagnosis in one series of 59 patients included [",
"    <a class=\"abstract\" href=\"UTD.htm?2/26/2474/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Abdominal distension &ndash; 75 percent",
"     </li>",
"     <li>",
"      Abdominal pain &ndash; 58 percent",
"     </li>",
"     <li>",
"      Nausea &ndash; 49 percent",
"     </li>",
"     <li>",
"      Constipation &ndash; 48 percent",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Heartburn/regurgitation",
"      </span>",
"      &ndash; 46 percent",
"     </li>",
"     <li>",
"      Fullness &ndash; 44 percent",
"     </li>",
"     <li>",
"      Epigastric",
"      <span class=\"nowrap\">",
"       pain/burning",
"      </span>",
"      &ndash; 34 percent",
"     </li>",
"     <li>",
"      Early satiety &ndash; 37 percent",
"     </li>",
"     <li>",
"      Vomiting &ndash; 36 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Acute episodes are characterized by abrupt onset of intense, cramping pain, abdominal distention, nausea, and vomiting. After the acute episode, patients may be asymptomatic or more often, continue to experience symptoms due to delayed transit in the proximal (eg, anorexia, early satiety nausea and vomiting)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    distal (constipation) gastrointestinal tract.",
"   </p>",
"   <p>",
"    Patients may have diarrhea due to small bowel bacterial overgrowth. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11990?source=see_link\">",
"     \"Clinical manifestations and diagnosis of small intestinal bacterial overgrowth\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Weight loss results from impaired intestinal transit, malabsorption due to bacterial overgrowth, and inadequate intake due to exacerbation of symptoms with food ingestion.",
"   </p>",
"   <p>",
"    Patients may have symptoms due to the underlying disorder (eg, dysphagia in CIPO related to Chagas disease, proximal muscle weakness leading to difficulty climbing stairs in patients with",
"    <span class=\"nowrap\">",
"     polymyositis/dermatomyositis,",
"    </span>",
"    bladder dysfunction in neuropathic and myopathic CIPO). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32458?source=see_link\">",
"     \"Epidemiology and clinical features of multiple sclerosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29224?source=see_link\">",
"     \"Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14503?source=see_link\">",
"     \"Clinical manifestations of hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36646?source=see_link\">",
"     \"Clinical manifestations of hypocalcemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/14/23786?source=see_link\">",
"     \"Clinical presentation and diagnosis of pheochromocytoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18551?source=see_link\">",
"     \"Clinical manifestations and diagnosis of diabetic polyneuropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/59/14266?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Chagas heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41848?source=see_link\">",
"     \"Congenital aganglionic megacolon (Hirschsprung disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patient may provide a history of culprit medications (including anticholinergic antidepressants, calcium channel blockers, and the alpha-2 adrenergic agonists such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    ) or a family history of relatives with a similar clinical presentation (eg, MNGIE, familial amyloidosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/26/2474/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21210385\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main physical findings are abdominal distention, abdominal tenderness on palpation (localized to the epigastric and periumbilical regions or more commonly, over the whole abdomen), and a succussion splash. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/47/44793?source=see_link&amp;anchor=H16#H16\">",
"     \"Gastric outlet obstruction in adults\", section on 'Physical examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients may also have signs of an underlying collagen vascular or neuromuscular disease (eg, proximal muscle weakness may indicate",
"    <span class=\"nowrap\">",
"     polymyositis/dermatomyositis;",
"    </span>",
"    classic skin abnormalities associated with scleroderma; ptosis, ophthalmoplegia, peripheral polyneuropathy, and sensorineural hearing loss in MNGIE). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29224?source=see_link\">",
"     \"Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32458?source=see_link\">",
"     \"Epidemiology and clinical features of multiple sclerosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21210740\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of serum electrolytes may reveal hypokalemia and metabolic acidosis if there is prominent diarrhea. Hypokalemia and metabolic alkalosis may be present if there is prominent vomiting. Patients may also have unexplained hypoalbuminemia due to malnutrition. Rarely, serum vitamin B12 concentrations are low due to bacterial overgrowth. Patients may have an elevated TSH due to underlying hypothyroidism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21210900\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;A plain film of the abdomen in intestinal pseudo-obstruction usually demonstrates air-fluid levels",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    distended loops of small bowel. In addition, computed tomographic",
"    <span class=\"nowrap\">",
"     (CT)/magnetic",
"    </span>",
"    resonance (MR) enterography may demonstrate dilated loops and rarely diverticula or pneumatosis intestinalis.",
"   </p>",
"   <p>",
"    Radiographic testing does not usually provide an etiologic diagnosis of CIPO. An exception is systemic sclerosis affecting the small intestine, which is characterized by dilated segments, edema, and abnormal texture and motility of the valvulae conniventes (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65344 \" href=\"UTD.htm?0/45/721\">",
"     image 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/35/41529?source=see_link&amp;anchor=H22#H22\">",
"     \"Gastrointestinal manifestations of systemic sclerosis (scleroderma)\", section on 'Radiographic findings'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61539017\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of chronic intestinal pseudo-obstruction (CIPO) is based on the presence of longstanding symptoms of mechanical obstruction in the absence of an anatomic cause on radiologic examination and endoscopy, and evidence of impaired motility.",
"   </p>",
"   <p>",
"    Confirmation of the diagnosis requires exclusion of mechanical obstruction and other causes of dysmotility by performing imaging studies, endoscopy, and scintigraphy to assess motility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4427970\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;When there is clinical suspicion of CIPO due to symptoms of obstruction, patients should undergo initial evaluation with radiographic testing to exclude organic causes of obstruction. Plain x-rays identify air fluid levels, and contrast imaging (computed tomographic",
"    <span class=\"nowrap\">",
"     [CT]/magnetic",
"    </span>",
"    resonance [MR] enterography) identifies an organic cause of obstruction. MR angiography should be considered in patients with evidence of obstruction when congenital or acquired vascular abnormalities are suspected based on enterography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83057611\">",
"    <span class=\"h2\">",
"     Endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upper endoscopy and colonoscopy should be performed to rule out an intraluminal or extraluminal cause of obstruction and to identify the location of the obstruction (upper [gastrojejunal] or lower [ileocolonic] gastrointestinal tract). Upper gastrointestinal endoscopy is useful to exclude an aortomesenteric artery compression syndrome, which may be difficult to differentiate on imaging from CIPO due to the impact of severe dysmotility on this segment of the small intestine (ie, sustained uncoordinated contractions in the distal duodenum). The duodenal mucosa should be biopsied to exclude celiac disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83057808\">",
"    <span class=\"h2\">",
"     Motility assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients in whom CIPO is suspected and there is no evidence of an intraluminal or extraluminal cause of obstruction on imaging and by endoscopy, the presence of a motility disorder should be confirmed with scintigraphy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83057815\">",
"    <span class=\"h3\">",
"     Scintigraphy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scintigraphy is the method of choice in the evaluation of gastric, small bowel, and colon transit.",
"   </p>",
"   <p>",
"    While interpreting scintigraphy results, it is important to note that delayed colonic transit may cause delayed small bowel transit. Therefore, it is important to consider gastrointestinal transit in all three main regions (stomach, small bowel, and colon) before concluding that delayed small bowel transit defines small intestinal dysmotility. A useful clue to clinically significant small intestinal disease is the finding of delayed gastric emptying [",
"    <a class=\"abstract\" href=\"UTD.htm?2/26/2474/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Thus, when small bowel and colonic transit are delayed and gastric emptying is normal, the main focus of treatment should be normalization of colonic motor function and treatment of constipation. Novel approaches using fewer scans have been devised to simplify the evaluation of bowel transit using scintigraphy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/26/2474/abstract/23-25\">",
"     23-25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83057822\">",
"    <span class=\"h3\">",
"     Wireless motility capsule",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small bowel transit in suspected chronic intestinal dysmotility can also be measured by wireless motility capsule, which assesses small bowel transit time by a sharp increase in pH on entry into the duodenum and by a fall in pH at the ileocecal junction [",
"    <a class=\"abstract\" href=\"UTD.htm?2/26/2474/abstract/26\">",
"     26",
"    </a>",
"    ]. Evaluation of intestinal motility using endoluminal image analysis acquired by capsule has also been developed [",
"    <a class=\"abstract\" href=\"UTD.htm?2/26/2474/abstract/27\">",
"     27",
"    </a>",
"    ]. However, further validation of these techniques is needed before they can be routinely used to assess motility. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16568?source=see_link\">",
"     \"Motility testing: When does it help?\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/22/13673?source=see_link&amp;anchor=H1228743000#H1228743000\">",
"     \"Etiology and evaluation of chronic constipation in adults\", section on 'Wireless motility capsule'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4427843\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic intestinal dysmotility and slow transit",
"    <span class=\"nowrap\">",
"     constipation/colon",
"    </span>",
"    inertia are similar motor disorders of the small bowel and colon, which are not associated with dilatation (",
"    <a class=\"graphic graphic_table graphicRef73822 \" href=\"UTD.htm?7/36/7755\">",
"     table 1",
"    </a>",
"    ). Chronic intestinal pseudo-obstruction can be distinguished from mechanical obstruction and other acute functional causes of obstruction (eg, postoperative ileus and acute pseudo-obstruction) based on the time course, location of dilation, symptom progression, and findings on imaging (",
"    <a class=\"graphic graphic_table graphicRef84010 \" href=\"UTD.htm?39/57/40860\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17216966\">",
"    <span class=\"h1\">",
"     IDENTIFYING THE ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the diagnosis of chronic intestinal pseudo-obstruction (CIPO) is established, the underlying etiology should be determined. All patients should undergo laboratory testing to identify secondary causes of CIPO.",
"   </p>",
"   <p>",
"    In patients with delayed transit on scintigraphy, in whom there is a known underlying disease, no further investigation is necessary (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Etiology'",
"    </a>",
"    above). In patients with delayed transit and no known underlying disease, manometry should be performed. Autonomic testing is useful in patients with evidence of neuropathic dysmotility on manometry, but without a known underlying neurologic disorder. Full thickness biopsy is rarely needed and should be considered in patients with severe dysmotility of unknown etiology who undergo surgery, in patients with poor postsurgical outcomes, or in patients with a permanent catheter for enteral or parenteral nutrition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H209092\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory examination can identify secondary causes of CIPO related to potentially curable diseases. The following tests should therefore be performed in all patients with CIPO: complete blood count, electrolytes, liver tests, vitamin B12, folate, celiac serologies, thyrotropin (TSH), serologic testing for herpes simplex virus (HSV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), markers of inflammation including erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP).",
"   </p>",
"   <p>",
"    Antineuronal antibodies",
"    <span class=\"nowrap\">",
"     (ANNA-1/anti-Hu)",
"    </span>",
"    should be sought in patients with suspected paraneoplastic syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?2/26/2474/abstract/28\">",
"     28",
"    </a>",
"    ]. In patients with suspected mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) lactic acid (at rest and during exercise), thymidine phosphorylase levels in the buffy coat, nucleotide concentrations, and genetic analysis should be performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Manometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Manometric studies of the stomach and small intestine should be performed in patients with abnormal motility on scintigraphy, but no known underlying disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/26/2474/abstract/29\">",
"     29",
"    </a>",
"    ]. Manometry plays a supportive role in defining the underlying diagnosis, but lacks specificity. Myopathic disorders are typically associated with low amplitude contractions, whereas in neuropathic disorders, the amplitude of contractions is typically normal, but the organization of the contractile response is abnormal (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51540 \" href=\"UTD.htm?13/12/13509\">",
"     image 2",
"    </a>",
"    ). A mechanical obstruction of the intestine typically shows simultaneous, prolonged contractions at the level of the small intestine [",
"    <a class=\"abstract\" href=\"UTD.htm?2/26/2474/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23288519\">",
"    <span class=\"h3\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Manometry is performed by placement of a multilumen tube through the nose or mouth into the small intestine. Positioning of the tube is facilitated by endoscopy or a steerable catheter system to place a guidewire through the stomach and duodenum and into the jejunum. Perfusion of the lumens or solid state transducers placed along the tube allows measurement of the pressure profile of the stomach and small intestine. These profiles are measured over several hours during fasting and after standard meals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Autonomic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autonomic testing is useful in patients with evidence of neuropathic dysmotility on manometry, but without a known underlying neurologic disorder. Several common neurologic disorders can affect gastrointestinal motility by altering the parasympathetic or sympathetic supply to the gut (",
"    <a class=\"graphic graphic_figure graphicRef52708 \" href=\"UTD.htm?17/3/17459\">",
"     figure 1",
"    </a>",
"    ). These include [",
"    <a class=\"abstract\" href=\"UTD.htm?2/26/2474/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Brainstem tumors or strokes",
"     </li>",
"     <li>",
"      Diabetes mellitus",
"     </li>",
"     <li>",
"      Spinal cord injury",
"     </li>",
"     <li>",
"      Multiple sclerosis",
"     </li>",
"     <li>",
"      Parkinson disease",
"     </li>",
"     <li>",
"      Autonomic system degeneration",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Tests of autonomic function can differentiate a preganglionic or central lesion from a peripheral neuropathy associated with autonomic dysfunction (",
"    <a class=\"graphic graphic_table graphicRef82750 \" href=\"UTD.htm?7/13/7387\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/26/2474/abstract/31\">",
"     31",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Brain and spinal cord magnetic resonance imaging (MRI) is essential in patients in whom a central lesion is suggested from the history or the results of autonomic testing. A peripheral dysautonomia requires further screening for a toxic, metabolic, or paraneoplastic process (eg, lead poisoning, porphyria, or lung cancer, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Full-thickness intestinal biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Full thickness biopsies should be considered in patients with severe dysmotility of unknown etiology who undergo surgery for any reason especially in those refractory to therapy, in patients with poor postsurgical outcomes, or in patients with a permanent catheter for enteral or parenteral nutrition. Histologic findings may help differentiate myopathic, neuropathic, or other disorders. Histopathologic techniques also allow for detection of subtle abnormalities in the enteric nervous system and underlying deficiencies in specific neuropeptides and neurotransmitters, thereby providing valuable information for diagnosis, prognosis, and management [",
"    <a class=\"abstract\" href=\"UTD.htm?2/26/2474/abstract/1,6,32,33\">",
"     1,6,32,33",
"    </a>",
"    ]. Case reports have described histologic findings on full-thickness specimens",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    their correlation to manometric findings [",
"    <a class=\"abstract\" href=\"UTD.htm?2/26/2474/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21210489\">",
"     'Prognosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The basic principles of management of chronic intestinal pseudo-obstruction (CIPO) are based predominantly upon clinical experience.",
"   </p>",
"   <p>",
"    Patients should be managed by a multidisciplinary team including a gastroenterologist, nutritionist, and transplant surgeon with experience in the treatment of CIPO [",
"    <a class=\"abstract\" href=\"UTD.htm?2/26/2474/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with CIPO require supplemental nutritional support. Prokinetics may be useful for acute and chronic therapy of intestinal pseudo-obstruction. Antibiotics are recommended in patients with small bowel bacterial overgrowth. Immunomodulator therapy should be reserved for patients with CIPO due to an established underlying inflammatory neuropathy. Surgery should be performed, if necessary, to provide access for",
"    <span class=\"nowrap\">",
"     venting/feeding.",
"    </span>",
"    Surgery to resect or bypass localized disease of the small bowel should be avoided. Intestinal transplantation is indicated in selected patients in whom long-term parenteral nutrition cannot be initiated or continued safely.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Nutritional support",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early intervention with nutritional support is important, particularly for those who have had recurrent vomiting or reduced oral intake. Small meals consisting of liquid or homogenized foods are better tolerated than solids. Hypercaloric liquid formulations should be used in patients with low caloric intake. Oral or enteral nutrition is typically used for neuropathic disorders or in patients in whom the motility disorder is localized to the stomach and duodenum. Parenteral nutrition may be necessary for patients with severe dysmotility (usually myopathic pseudo-obstruction). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13831?source=see_link\">",
"     \"Nutrition support in critically ill patients: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Prokinetic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prokinetic agents, particularly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    and cisapride, may be useful for acute and chronic therapy of intestinal pseudo-obstruction, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?2/26/2474/abstract/38\">",
"     38",
"    </a>",
"    ]. However, these treatments are off-label and risks and benefits should be discussed with the patient.",
"   </p>",
"   <p>",
"    It is appropriate to combine a prokinetic agent with an antiemetic medication such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/20/15688?source=see_link\">",
"     promethazine",
"    </a>",
"    12.5 to 25 mg twice daily (also available in liquid form or suppository) for symptom relief. The sedative effects of promethazine may be helpful when administered at bedtime. In patients who cannot tolerate promethazine, the 5-HT3 antagonist",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    4 to 8 mg three times daily may be used. However, this class of medications delays colonic transit. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19208?source=see_link\">",
"     \"Characteristics of antiemetic drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Erythromycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    is effective during acute exacerbations of intestinal pseudo-obstruction, acting at least in part by stimulation of the motilin receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?2/26/2474/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Such patients are typically hospitalized and require intravenous fluids. Intravenous erythromycin lactobionate at a dose of 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every eight hours should be continued for at least five to seven days.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     Erythromycin",
"    </a>",
"    has not been very effective for chronic therapy and has only been tried in a small number of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/26/2474/abstract/41\">",
"     41",
"    </a>",
"    ]. Oral cisapride should",
"    <strong>",
"     not",
"    </strong>",
"    be given to patients receiving erythromycin, since there is a potential risk of drug interaction leading to significant arrhythmia (torsades de pointes). There is some evidence that intravenous erythromycin may be effective in patients with upper gut motility disorders due to scleroderma, but clinical experience is only anecdotal [",
"    <a class=\"abstract\" href=\"UTD.htm?2/26/2474/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4428317\">",
"    <span class=\"h3\">",
"     Prucalopride",
"    </span>",
"    &nbsp;&mdash;&nbsp;Available in Europe and not in the United States,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/10/18596?source=see_link\">",
"     prucalopride",
"    </a>",
"    is a 5HT4 agonist. Prucalopride accelerates transit through the stomach, small bowel, and colon [",
"    <a class=\"abstract\" href=\"UTD.htm?2/26/2474/abstract/43\">",
"     43",
"    </a>",
"    ]. Prucalopride appears promising in the treatment of CIPO. In a randomized, double-blind, crossover study, prucalopride appeared to provide symptom relief in four of seven patients with CIPO. In three patients with visceral myopathy and one visceral neuropathy, 2 to 4 mg prucalopride (relative to placebo) significantly improved pain in three of four patients, nausea in two, vomiting in one, and bloating in four, whereas bowel function was not changed substantially [",
"    <a class=\"abstract\" href=\"UTD.htm?2/26/2474/abstract/44\">",
"     44",
"    </a>",
"    ]. In contrast to cisapride, prucalopride appears to have much lower risk of cardiac arrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/26/2474/abstract/45\">",
"     45",
"    </a>",
"    ], even in the elderly [",
"    <a class=\"abstract\" href=\"UTD.htm?2/26/2474/abstract/46\">",
"     46",
"    </a>",
"    ], based on studies performed in patients with chronic constipation. The recommended dose of prucalopride in patients with CIPO is 2 mg daily in adults and 1 mg daily in those &gt;65 years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10337011\">",
"    <span class=\"h3\">",
"     Cisapride",
"    </span>",
"    &nbsp;&mdash;&nbsp;In randomized trials, oral cisapride at a dose of 20 mg three times a day was effective in improving gastric emptying but did not provide symptomatic relief in patients with CIPO [",
"    <a class=\"abstract\" href=\"UTD.htm?2/26/2474/abstract/38,47-49\">",
"     38,47-49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, in a randomized controlled trial in which 42 neuropathic patients (gastroparesis or intestinal dysmotility or CIPO) were randomized to cisapride at a dose of 10 or 20 mg three times daily or placebo for 12 weeks, overall symptom responses with cisapride were more likely in patients without coexisting vagal denervation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/26/2474/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cisapride has been associated with a number of drug interactions and fatal cardiac arrhythmias, prompting the manufacturer to severely limit its availability in the United States, although it remains available in other countries. Prescriptions for the drug can only be filled directly through the manufacturer after providing documentation as to need for the drug and assessment of risk factors for cardiac arrhythmias in the individual patient. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Metoclopramide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    is an alternative in patients with an acute exacerbation of intestinal pseudo-obstruction who cannot tolerate",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    . Metoclopramide may help initiate motility if the patient does not have prior evidence of adverse effects with metoclopramide and cannot tolerate erythromycin. Thus, metoclopramide may help during acute exacerbations at doses that are tolerated (usually 10 mg four times daily). A possible history of an extrapyramidal reaction to this agent should be elicited prior to beginning therapy. There is no evidence that metoclopramide is effective in the long-term treatment of pseudo-obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?2/26/2474/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4428226\">",
"    <span class=\"h3\">",
"     Octreotide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with scleroderma may benefit from subcutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    (a long-acting somatostatin analogue). A single study has reported success in treating five such patients with 50 mcg of octreotide administered subcutaneously at bedtime [",
"    <a class=\"abstract\" href=\"UTD.htm?2/26/2474/abstract/52\">",
"     52",
"    </a>",
"    ]. Octreotide caused an average of 3.6 migrating motor complexes (MMC) in three hours of small bowel recordings when there had previously been none. A similar benefit to intestinal motility with improvement in symptoms was observed in a few patients with idiopathic intestinal pseudo-obstruction, especially in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/26/2474/abstract/53\">",
"     53",
"    </a>",
"    ]. However, it is important to be aware that when octreotide is administered during the daytime with meals, it significantly delays gastric emptying and small bowel transit of solids [",
"    <a class=\"abstract\" href=\"UTD.htm?2/26/2474/abstract/54,55\">",
"     54,55",
"    </a>",
"    ], which may be deleterious to patients with CIPO. Therefore, it is recommended that if octreotide is used in CIPO, it should be administered before bed, at least two hours after the last meal, and its main purpose is to induce MMCs and thereby reduce the risk of bacterial overgrowth in patients with CIPO.",
"   </p>",
"   <p>",
"    Symptomatic improvement with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    may reflect changes in visceral afferent function rather than an effect upon transit through the intestine [",
"    <a class=\"abstract\" href=\"UTD.htm?2/26/2474/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42716700\">",
"    <span class=\"h2\">",
"     Neostigmine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case reports have suggested that acute exacerbation of intestinal pseudo-obstruction may respond to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/41/10901?source=see_link\">",
"     neostigmine",
"    </a>",
"    (0.5 mg intramuscular or intravenous over five minutes with cardiac monitoring) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/26/2474/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. If the patient has received mu-opiates, there may also be a response to subcutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/29/2516?source=see_link\">",
"     methylnaltrexone",
"    </a>",
"    (0.15",
"    <span class=\"nowrap\">",
"     mg/kg).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4428094\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients",
"    with CIPO who have steatorrhea, vitamin B12 malabsorption, or folate excess may have bacterial overgrowth and should be treated empirically with antibiotics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28454?source=see_link\">",
"     \"Treatment of small intestinal bacterial overgrowth\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Jejunal cultures are needed if steatorrhea does not respond to empiric antibiotics. Jejunal aspirate is the preferred test for diagnosing bacterial overgrowth in patients with CIPO as breath tests for bacterial overgrowth have a high false negative rate in patients with motility disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?2/26/2474/abstract/59\">",
"     59",
"    </a>",
"    ]. The finding of &ge;10",
"    <sup>",
"     5",
"    </sup>",
"    aerobic colony forming",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    in the jejunal aspirate (normal jejunal concentration is &le;10",
"    <sup>",
"     4",
"    </sup>",
"    aerobic colony forming",
"    <span class=\"nowrap\">",
"     units/mL)",
"    </span>",
"    is consistent with bacterial overgrowth. Antibiotics are rotated with drug-free intervals of at least 15 days in an attempt to avoid the development of bacterial resistance. In some patients with severe myopathic disease, it may be necessary to use \"rotating\" antibiotics (eg, week on, week off). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28454?source=see_link\">",
"     \"Treatment of small intestinal bacterial overgrowth\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Immunomodulator therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case reports have described intestinal pseudo-obstruction in association with lymphocytic infiltration of the myenteric plexus [",
"    <a class=\"abstract\" href=\"UTD.htm?2/26/2474/abstract/1,60\">",
"     1,60",
"    </a>",
"    ] or smooth muscle [",
"    <a class=\"abstract\" href=\"UTD.htm?2/26/2474/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. These observations suggest a potential role for immunomodulator therapy. Immunomodulator therapy should be reserved for patients with CIPO due to an underlying inflammatory neuropathy that is established by biopsy or by the presence of antineuronal antibodies (anti-Hu) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/26/2474/abstract/32\">",
"     32",
"    </a>",
"    ]. The most common immunosuppressive agents used are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    starting at 40 to 60 mg daily. In one case report, paraneoplastic pseudo-obstruction in the setting of small cell lung cancer was reported to respond to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/26/2474/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of surgery in the management of CIPO is to provide access to the stomach or small bowel for venting (decompression to relieve symptoms) and feeding, both of which may be performed laparoscopically.",
"   </p>",
"   <p>",
"    Resection of localized disease should be avoided in patients with CIPO. Clinical experience suggests that even though the disease may appear to be localized, it usually becomes evident in the remaining bowel, thereby rendering the benefits of a bypass temporary. Repeated surgery also leads to diagnostic confusion, making it difficult to distinguish CIPO from small bowel obstruction. Subtotal enterectomy for pseudo-obstruction has been performed for relief of severe pain associated with markedly distended loops of intestine. In such cases, the patient is committed to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    for life as a consequence of surgery. Bypass of dilated segments has been suggested for patients with megaduodenum. However, in our experience, this procedure has been ineffective in patients with persistent symptoms.",
"   </p>",
"   <p>",
"    Pacing of the intestine and electrical stimulation of the stomach or intestine are considered experimental at this time, although initial results have been favorable. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31574?source=see_link\">",
"     \"Electrical stimulation for gastroparesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10336758\">",
"    <span class=\"h2\">",
"     Percutaneous endoscopic colostomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colonoscopic insertion of a gastrostomy tube into the colon to relieve obstructive symptoms has been described in case reports. While the safety and long-term efficacy of this approach remain to be established, improvement in symptoms for up to two years has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?2/26/2474/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11534996\">",
"    <span class=\"h2\">",
"     Intestinal transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intestinal transplantation is indicated in patients in whom long-term parenteral nutrition cannot be initiated or continued safely. Intestinal transplantation for patients with motility disorders has been performed less frequently than for patients with short bowel syndrome.",
"   </p>",
"   <p>",
"    Graft rejection, graft-versus-host disease, and immunosuppression-related lymphoproliferative disorders are more common with small intestinal transplantation than after other organ transplants [",
"    <a class=\"abstract\" href=\"UTD.htm?2/26/2474/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. However, the results of intestinal transplantation have improved over the past decade. As a result of surgical advances, control of acute cellular rejection, and a decrease in lethal infections, the rate of patient survival at one year now exceeds 90 percent at experienced centers.",
"   </p>",
"   <p>",
"    Intestinal transplantation may be life-saving in children, but is indicated only in patients in whom long-term parenteral nutrition cannot be performed or continued safely [",
"    <a class=\"abstract\" href=\"UTD.htm?2/26/2474/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/29/1497?source=see_link\">",
"     \"Overview of intestinal and multivisceral transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21210489\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of clinical, histopathological, and manometric features have been identified as being predictive of outcomes in patients with chronic intestinal pseudo-obstruction (CIPO) (",
"    <a class=\"graphic graphic_table graphicRef86277 \" href=\"UTD.htm?18/2/18476\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/26/2474/abstract/69,70\">",
"     69,70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The long-term outcome is often especially poor in children, with 60 to 80 percent requiring parenteral nutrition and a mortality rate ranging from 10 to 25 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/26/2474/abstract/71,72\">",
"     71,72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In adults with CIPO, the vast majority of patients have evidence of nutritional compromise, and almost one-third require long-term home parenteral nutrition (HPN) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/26/2474/abstract/69\">",
"     69",
"    </a>",
"    ]. Mortality rates of approximately 10 percent have been reported in adults, including HPN-related complications in 45 to 80 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?2/26/2474/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one series in adults that included 59 consecutive patients identified between 1985 and 2001 who were followed for a median of 4.6 years, symptoms associated with CIPO became progressively more severe with time [",
"    <a class=\"abstract\" href=\"UTD.htm?2/26/2474/abstract/19\">",
"     19",
"    </a>",
"    ]. Most patients had undergone a potentially dangerous surgery (mean 2.96 per patient) before a diagnosis was established, underscoring the need to recognize its presentation. Long-term outcomes were poor despite medical and surgical treatment. Approximately one-third of patients required long-term HPN, while about two-thirds had some nutritional limitation. Four patients underwent small bowel transplantation. Overall, 10 percent of patients died of disease-related complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic intestinal pseudo-obstruction (CIPO) is a syndrome that suggests mechanical bowel obstruction of the small or large bowel in the absence of an anatomic lesion that obstructs the flow of intestinal contents. Segments of affected bowel appear dilated on radiography. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Abdominal pain and distension are the most common clinical features. Patients may have diarrhea due to small bowel bacterial overgrowth. Nausea, vomiting, and weight loss are predominant symptoms in patients with CIPO involving the proximal gastrointestinal tract. Other features include anorexia, alternating bowel habits, and urinary symptoms. These symptoms may be acute, recurrent, or chronic. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of CIPO is based on the presence of longstanding symptoms of obstruction in the absence of an anatomic cause of obstruction despite endoscopy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      radiologic examination, and confirmation of impaired motility with scintigraphy. (See",
"      <a class=\"local\" href=\"#H61539017\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients should undergo laboratory testing to identify secondary causes of CIPO. (See",
"      <a class=\"local\" href=\"#H209092\">",
"       'Laboratory studies'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      In patients with abnormal transit on scintigraphy and in whom there is a known underlying disease, no further investigation is necessary and appropriate therapy can be initiated. In patients with abnormal transit on scintigraphy and no known underlying disease, manometry should be performed. (See",
"      <a class=\"local\" href=\"#H17216966\">",
"       'Identifying the etiology'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Autonomic testing is useful in patients with evidence of a neuropathic disorder on manometry, but without a known underlying neurologic disorder. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Autonomic testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nutritional support is important, particularly for those who have had recurrent vomiting or reduced oral intake. Small meals consisting of liquid or homogenized foods are better tolerated than solids. Hypercaloric liquid formulations should be used in patients with low caloric intake. Oral or enteral nutrition is typically used for neuropathic disorders or in whom the motility disorder is localized to the stomach and duodenum. Parenteral nutrition may be necessary for patients with severe dysmotility (usually myopathic pseudo-obstruction). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Nutritional support'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with CIPO who have steatorrhea, vitamin B12 malabsorption, or folate excess (suggestive of bacterial overgrowth), we suggest empiric treatment with antibiotics (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Jejunal aspirate cultures are needed if steatorrhea does not respond to empiric antibiotics. Antibiotics, usually on a rotating basis, are used in patients who have confirmed small bowel bacterial overgrowth. (See",
"      <a class=\"local\" href=\"#H4428094\">",
"       'Antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For symptomatic relief in patients with CIPO, we suggest that prokinetic agents, particularly",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      for acute exacerbations of CIPO. For chronic symptoms of CIPO, we suggest cisapride, or where it is available,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/10/18596?source=see_link\">",
"       prucalopride",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Prokinetic agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgery should be performed to provide access to the stomach or small bowel for venting and feeding. Resection of localized disease should be avoided in patients with CIPO. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intestinal transplantation is indicated in patients in whom long-term parenteral nutrition cannot be initiated or continued safely. (See",
"      <a class=\"local\" href=\"#H11534996\">",
"       'Intestinal transplantation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/1\">",
"      De Giorgio R, Sarnelli G, Corinaldesi R, Stanghellini V. Advances in our understanding of the pathology of chronic intestinal pseudo-obstruction. Gut 2004; 53:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/2\">",
"      Hall KE, Wiley JW. Neural injury, repair and adaptation in the GI tract. I. New insights into neuronal injury: a cautionary tale. Am J Physiol 1998; 274:G978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/3\">",
"      Sodhi N, Camilleri M, Camoriano JK, et al. Autonomic function and motility in intestinal pseudoobstruction caused by paraneoplastic syndrome. Dig Dis Sci 1989; 34:1937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/4\">",
"      Darnell RB, DeAngelis LM. Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies. Lancet 1993; 341:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/5\">",
"      Lennon VA, Sas DF, Busk MF, et al. Enteric neuronal autoantibodies in pseudoobstruction with small-cell lung carcinoma. Gastroenterology 1991; 100:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/6\">",
"      De Giorgio R, Stanghellini V, Barbara G, et al. Primary enteric neuropathies underlying gastrointestinal motor dysfunction. Scand J Gastroenterol 2000; 35:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/7\">",
"      Ruuska TH, Karikoski R, Smith VV, Milla PJ. Acquired myopathic intestinal pseudo-obstruction may be due to autoimmune enteric leiomyositis. Gastroenterology 2002; 122:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/8\">",
"      Ohlsson B, Veress B, Janciauskiene S, et al. Chronic intestinal pseudo-obstruction due to buserelin-induced formation of anti-GnRH antibodies. Gastroenterology 2007; 132:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/9\">",
"      T&ouml;rnblom H, Lang B, Clover L, et al. Autoantibodies in patients with gut motility disorders and enteric neuropathy. Scand J Gastroenterol 2007; 42:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/10\">",
"      Selgrad M, De Giorgio R, Fini L, et al. JC virus infects the enteric glia of patients with chronic idiopathic intestinal pseudo-obstruction. Gut 2009; 58:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/11\">",
"      Mariani A, Camilleri M, Petersen IA, et al. Audit of suspected chronic intestinal pseudo-obstruction in patients with gynecologic cancer. Eur J Gynaecol Oncol 2008; 29:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/12\">",
"      Stanghellini V, Corinaldesi R, Barbara L. Pseudo-obstruction syndromes. Baillieres Clin Gastroenterol 1988; 2:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/13\">",
"      Coulie B, Camilleri M. Intestinal pseudo-obstruction. Annu Rev Med 1999; 50:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/14\">",
"      Pingault V, Bondurand N, Kuhlbrodt K, et al. SOX10 mutations in patients with Waardenburg-Hirschsprung disease. Nat Genet 1998; 18:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/15\">",
"      Di Nardo G, Blandizzi C, Volta U, et al. Review article: molecular, pathological and therapeutic features of human enteric neuropathies. Aliment Pharmacol Ther 2008; 28:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/16\">",
"      Deglincerti A, De Giorgio R, Cefle K, et al. A novel locus for syndromic chronic idiopathic intestinal pseudo-obstruction maps to chromosome 8q23-q24. Eur J Hum Genet 2007; 15:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/17\">",
"      O'Donnell AM, Puri P. A role for Pten in paediatric intestinal dysmotility disorders. Pediatr Surg Int 2011; 27:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/18\">",
"      Stanghellini V, Camilleri M, Malagelada JR. Chronic idiopathic intestinal pseudo-obstruction: clinical and intestinal manometric findings. Gut 1987; 28:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/19\">",
"      Stanghellini V, Cogliandro RF, De Giorgio R, et al. Natural history of chronic idiopathic intestinal pseudo-obstruction in adults: a single center study. Clin Gastroenterol Hepatol 2005; 3:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/20\">",
"      Camilleri M. Disorders of gastrointestinal motility in neurologic diseases. Mayo Clin Proc 1990; 65:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/21\">",
"      Mayer EA, Elashoff J, Hawkins R, et al. Gastric emptying of mixed solid-liquid meal in patients with intestinal pseudoobstruction. Dig Dis Sci 1988; 33:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/22\">",
"      Camilleri M, Brown ML, Malagelada JR. Relationship between impaired gastric emptying and abnormal gastrointestinal motility. Gastroenterology 1986; 91:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/23\">",
"      Camilleri M, Zinsmeister AR, Greydanus MP, et al. Towards a less costly but accurate test of gastric emptying and small bowel transit. Dig Dis Sci 1991; 36:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/24\">",
"      von der Ohe MR, Camilleri M. Measurement of small bowel and colonic transit: indications and methods. Mayo Clin Proc 1992; 67:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/25\">",
"      Camilleri M, Zinsmeister AR. Towards a relatively inexpensive, noninvasive, accurate test for colonic motility disorders. Gastroenterology 1992; 103:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/26\">",
"      Kuo B, Maneerattanaporn M, Lee AA, et al. Generalized transit delay on wireless motility capsule testing in patients with clinical suspicion of gastroparesis, small intestinal dysmotility, or slow transit constipation. Dig Dis Sci 2011; 56:2928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/27\">",
"      Malagelada C, De Iorio F, Azpiroz F, et al. New insight into intestinal motor function via noninvasive endoluminal image analysis. Gastroenterology 2008; 135:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/28\">",
"      de Giorgio R, Volta U, Stanghellini V, et al. Neurogenic chronic intestinal pseudo-obstruction: antineuronal antibody-mediated activation of autophagy via Fas. Gastroenterology 2008; 135:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/29\">",
"      Camilleri M. Study of human gastroduodenojejunal motility. Applied physiology in clinical practice. Dig Dis Sci 1993; 38:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/30\">",
"      Camilleri M. Jejunal manometry in distal subacute mechanical obstruction: significance of prolonged simultaneous contractions. Gut 1989; 30:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/31\">",
"      Vassallo M, Camilleri M, Caron BL, Low PA. Gastrointestinal motor dysfunction in acquired selective cholinergic dysautonomia associated with infectious mononucleosis. Gastroenterology 1991; 100:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/32\">",
"      De Giorgio R, Camilleri M. Human enteric neuropathies: morphology and molecular pathology. Neurogastroenterol Motil 2004; 16:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/33\">",
"      Park SH, Min H, Chi JG, et al. Immunohistochemical studies of pediatric intestinal pseudo-obstruction: bcl2, a valuable biomarker to detect immature enteric ganglion cells. Am J Surg Pathol 2005; 29:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/34\">",
"      Lindberg G, T&ouml;rnblom H, Iwarzon M, et al. Full-thickness biopsy findings in chronic intestinal pseudo-obstruction and enteric dysmotility. Gut 2009; 58:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/35\">",
"      Ooms AH, Verheij J, Hulst JM, et al. Eosinophilic myenteric ganglionitis as a cause of chronic intestinal pseudo-obstruction. Virchows Arch 2012; 460:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/36\">",
"      van den Berg MM, Di Lorenzo C, Mousa HM, et al. Morphological changes of the enteric nervous system, interstitial cells of cajal, and smooth muscle in children with colonic motility disorders. J Pediatr Gastroenterol Nutr 2009; 48:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/37\">",
"      Goulet O, Sauvat F, Jan D. Surgery for pediatric patients with chronic intestinal pseudo-obstruction syndrome. J Pediatr Gastroenterol Nutr 2005; 41 Suppl 1:S66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/38\">",
"      Abell TL, Camilleri M, DiMagno EP, et al. Long-term efficacy of oral cisapride in symptomatic upper gut dysmotility. Dig Dis Sci 1991; 36:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/39\">",
"      Catnach SM, Fairclough PD. Erythromycin and the gut. Gut 1992; 33:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/40\">",
"      Emmanuel AV, Shand AG, Kamm MA. Erythromycin for the treatment of chronic intestinal pseudo-obstruction: description of six cases with a positive response. Aliment Pharmacol Ther 2004; 19:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/41\">",
"      Chami TN, Schuster MM, Crowell MD, et al. Effects of low dose erythromycin on gastrointestinal motility and symptoms in chronic intestinal pseudoobstruction (abstract). Gastroenterology 1991; 100:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/42\">",
"      Fiorucci S, Distrutti E, Bassotti G, et al. Effect of erythromycin administration on upper gastrointestinal motility in scleroderma patients. Scand J Gastroenterol 1994; 29:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/43\">",
"      Bouras EP, Camilleri M, Burton DD, et al. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology 2001; 120:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/44\">",
"      Emmanuel AV, Kamm MA, Roy AJ, et al. Randomised clinical trial: the efficacy of prucalopride in patients with chronic intestinal pseudo-obstruction--a double-blind, placebo-controlled, cross-over, multiple n = 1 study. Aliment Pharmacol Ther 2012; 35:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/45\">",
"      Camilleri M, Van Outryve MJ, Beyens G, et al. Clinical trial: the efficacy of open-label prucalopride treatment in patients with chronic constipation - follow-up of patients from the pivotal studies. Aliment Pharmacol Ther 2010; 32:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/46\">",
"      M&uuml;ller-Lissner S, Rykx A, Kerstens R, Vandeplassche L. A double-blind, placebo-controlled study of prucalopride in elderly patients with chronic constipation. Neurogastroenterol Motil 2010; 22:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/47\">",
"      Camilleri M, Brown ML, Malagelada JR. Impaired transit of chyme in chronic intestinal pseudoobstruction. Correction by cisapride. Gastroenterology 1986; 91:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/48\">",
"      Camilleri M. Appraisal of medium- and long-term treatment of gastroparesis and chronic intestinal dysmotility. Am J Gastroenterol 1994; 89:1769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/49\">",
"      Camilleri M, Malagelada JR, Abell TL, et al. Effect of six weeks of treatment with cisapride in gastroparesis and intestinal pseudoobstruction. Gastroenterology 1989; 96:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/50\">",
"      Camilleri M, Balm RK, Zinsmeister AR. Determinants of response to a prokinetic agent in neuropathic chronic intestinal motility disorder. Gastroenterology 1994; 106:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/51\">",
"      Lipton AB, Knauer CM. Pseudo-obstruction of the bowel. Therapeutic trial of metoclopramide. Am J Dig Dis 1977; 22:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/52\">",
"      Soudah HC, Hasler WL, Owyang C. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med 1991; 325:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/53\">",
"      Verne GN, Eaker EY, Hardy E, Sninsky CA. Effect of octreotide and erythromycin on idiopathic and scleroderma-associated intestinal pseudoobstruction. Dig Dis Sci 1995; 40:1892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/54\">",
"      von der Ohe MR, Camilleri M, Thomforde GM, Klee GG. Differential regional effects of octreotide on human gastrointestinal motor function. Gut 1995; 36:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/55\">",
"      Foxx-Orenstein A, Camilleri M, Stephens D, Burton D. Effect of a somatostatin analogue on gastric motor and sensory functions in healthy humans. Gut 2003; 52:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/56\">",
"      Hasler WL, Soudah HC, Owyang C. A somatostatin analogue inhibits afferent pathways mediating perception of rectal distention. Gastroenterology 1993; 104:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/57\">",
"      Borgaonkar MR, Lumb B. Acute on chronic intestinal pseudoobstruction responds to neostigmine. Dig Dis Sci 2000; 45:1644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/58\">",
"      Laustsen J, Harling H, Fallingborg J. Treatment of chronic idiopathic intestinal pseudoobstruction. Dig Dis Sci 1987; 32:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/59\">",
"      Valdovinos MA, Camilleri M, Thomforde GM, Frie C. Reduced accuracy of 14C-D-xylose breath test for detecting bacterial overgrowth in gastrointestinal motility disorders. Scand J Gastroenterol 1993; 28:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/60\">",
"      Ghirardo S, Sauter B, Levy G, et al. Primary intestinal autoimmune disease as a cause of chronic intestinal pseudo-obstruction. Gut 2005; 54:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/61\">",
"      Oton E, Moreira V, Redondo C, et al. Chronic intestinal pseudo-obstruction due to lymphocytic leiomyositis: is there a place for immunomodulatory therapy? Gut 2005; 54:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/62\">",
"      Haas S, Bindl L, Fischer HP. Autoimmune enteric leiomyositis: a rare cause of chronic intestinal pseudo-obstruction with specific morphological features. Hum Pathol 2005; 36:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/63\">",
"      Badari A, Farolino D, Nasser E, et al. A novel approach to paraneoplastic intestinal pseudo-obstruction. Support Care Cancer 2012; 20:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/64\">",
"      Thompson AR, Pearson T, Ellul J, Simson JN. Percutaneous endoscopic colostomy in patients with chronic intestinal pseudo-obstruction. Gastrointest Endosc 2004; 59:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/65\">",
"      Lee RG, Nakamura K, Tsamandas AC, et al. Pathology of human intestinal transplantation. Gastroenterology 1996; 110:1820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/66\">",
"      Quigley EM. Small intestinal transplantation: reflections on an evolving approach to intestinal failure. Gastroenterology 1996; 110:2009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/67\">",
"      Sigurdsson L, Reyes J, Kocoshis SA, et al. Intestinal transplantation in children with chronic intestinal pseudo-obstruction. Gut 1999; 45:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/68\">",
"      Sauvat F, Fusaro F, Lacaille F, et al. Is intestinal transplantation the future of children with definitive intestinal insufficiency? Eur J Pediatr Surg 2008; 18:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/69\">",
"      Stanghellini V, Cogliandro RF, de Giorgio R, et al. Chronic intestinal pseudo-obstruction: manifestations, natural history and management. Neurogastroenterol Motil 2007; 19:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/70\">",
"      Stanghellini V, Cogliandro RF, De Giorgio R, et al. Natural history of intestinal failure induced by chronic idiopathic intestinal pseudo-obstruction. Transplant Proc 2010; 42:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/71\">",
"      Mousa H, Hyman PE, Cocjin J, et al. Long-term outcome of congenital intestinal pseudoobstruction. Dig Dis Sci 2002; 47:2298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/72\">",
"      Faure C, Goulet O, Ategbo S, et al. Chronic intestinal pseudoobstruction syndrome: clinical analysis, outcome, and prognosis in 105 children. French-Speaking Group of Pediatric Gastroenterology. Dig Dis Sci 1999; 44:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/26/2474/abstract/73\">",
"      Mann SD, Debinski HS, Kamm MA. Clinical characteristics of chronic idiopathic intestinal pseudo-obstruction in adults. Gut 1997; 41:675.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2639 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-90976AC03E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_26_2474=[""].join("\n");
var outline_f2_26_2474=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Degenerative neuropathies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Paraneoplastic immune-mediated pseudo-obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Immune-mediated pseudo-obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Infectious",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Radiotherapy and chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10337704\">",
"      Genetic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4427919\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21210385\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21210740\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21210900\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H61539017\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4427970\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H83057611\">",
"      Endoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H83057808\">",
"      Motility assessment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H83057815\">",
"      - Scintigraphy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H83057822\">",
"      - Wireless motility capsule",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4427843\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17216966\">",
"      IDENTIFYING THE ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H209092\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Manometry",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23288519\">",
"      - Technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Autonomic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Full-thickness intestinal biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Nutritional support",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Prokinetic agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Erythromycin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4428317\">",
"      - Prucalopride",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10337011\">",
"      - Cisapride",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Metoclopramide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4428226\">",
"      - Octreotide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42716700\">",
"      Neostigmine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4428094\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Immunomodulator therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10336758\">",
"      Percutaneous endoscopic colostomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11534996\">",
"      Intestinal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21210489\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2639\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2639|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?0/45/721\" title=\"diagnostic image 1\">",
"      Intestinal pseudo-obstruction in scleroderma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?13/12/13509\" title=\"diagnostic image 2\">",
"      Manometry PSS DM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2639|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/3/17459\" title=\"figure 1\">",
"      Neuromuscular disorders impairing gastric motor function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2639|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/36/7755\" title=\"table 1\">",
"      GI motility disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/57/40860\" title=\"table 2\">",
"      Mechanical versus functional intestinal obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/13/7387\" title=\"table 3\">",
"      Tests of autonomic function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/2/18476\" title=\"table 4\">",
"      Prognostic factors in chronic intestinal pseudo-obstruction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/50/22311?source=related_link\">",
"      Acute colonic pseudo-obstruction (Ogilvie's syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19208?source=related_link\">",
"      Characteristics of antiemetic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/59/14266?source=related_link\">",
"      Clinical manifestations and diagnosis of Chagas heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=related_link\">",
"      Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18551?source=related_link\">",
"      Clinical manifestations and diagnosis of diabetic polyneuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11990?source=related_link\">",
"      Clinical manifestations and diagnosis of small intestinal bacterial overgrowth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36646?source=related_link\">",
"      Clinical manifestations of hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14503?source=related_link\">",
"      Clinical manifestations of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/14/23786?source=related_link\">",
"      Clinical presentation and diagnosis of pheochromocytoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41848?source=related_link\">",
"      Congenital aganglionic megacolon (Hirschsprung disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31574?source=related_link\">",
"      Electrical stimulation for gastroparesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32458?source=related_link\">",
"      Epidemiology and clinical features of multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/44/1734?source=related_link\">",
"      Epidemiology of JC and BK virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/22/13673?source=related_link\">",
"      Etiology and evaluation of chronic constipation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/47/44793?source=related_link\">",
"      Gastric outlet obstruction in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/35/41529?source=related_link\">",
"      Gastrointestinal manifestations of systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16568?source=related_link\">",
"      Motility testing: When does it help?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13831?source=related_link\">",
"      Nutrition support in critically ill patients: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/29/1497?source=related_link\">",
"      Overview of intestinal and multivisceral transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40968?source=related_link\">",
"      Overview of paraneoplastic syndromes of the nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29224?source=related_link\">",
"      Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37304?source=related_link\">",
"      Paraneoplastic syndromes affecting peripheral nerve and muscle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28454?source=related_link\">",
"      Treatment of small intestinal bacterial overgrowth",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_26_2475="Initial oxygen flow in COPD";
var content_f2_26_2475=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F73572&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F73572&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommended initial oxygen settings to achieve ambient air PaO2 &gt;60 mmHg",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        PaO2 breathing room air (mmHg)",
"       </td>",
"       <td class=\"subtitle1\">",
"        FIO2 (percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Nasal cannula setting to achieve approximate FIO2 (L/min)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        45",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        32",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_26_2475=[""].join("\n");
var outline_f2_26_2475=null;
var title_f2_26_2476="Components newborn scrn";
var content_f2_26_2476=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F76630&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F76630&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Commonly included components of state newborn screening programs for conditions that cause intellectual disability",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Condition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical syndrome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Biotinidase deficiency",
"       </td>",
"       <td>",
"        Seizures, skin disorders, hearing loss, MR, death",
"       </td>",
"       <td>",
"        Daily biotin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital hypothyroidism",
"       </td>",
"       <td>",
"        Mental and growth retardation",
"       </td>",
"       <td>",
"        Thyroid hormone replacement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Galactosemia",
"       </td>",
"       <td>",
"        Cataracts, cirrhosis, MR, fatal sepsis",
"       </td>",
"       <td>",
"        Eliminate lactose, use soy for newborn sepsis evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Homocystinuria",
"       </td>",
"       <td>",
"        MR, osteoporosis, thromboembolic disease",
"       </td>",
"       <td>",
"        Dietary restrictions, supplemental medicines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maple Syrup Urine disease",
"       </td>",
"       <td>",
"        Feeding problems, vomiting, death; severe MR",
"       </td>",
"       <td>",
"        Branched-chain amino acids/dietary restrictions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phenylketonuria",
"       </td>",
"       <td>",
"        MR, seizures, eczema",
"       </td>",
"       <td>",
"        Phenylalanine restricted diet",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital toxoplasmosis",
"       </td>",
"       <td>",
"        Hydrocephalus, MR, splenomegaly, ascites",
"       </td>",
"       <td>",
"        One year of regimented antibiotics, ID consult",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Newborn hearing screen",
"       </td>",
"       <td>",
"        Global delay in cognitive and social development",
"       </td>",
"       <td>",
"        <p>",
"         Hearing aids",
"        </p>",
"        Special Education",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MR: mental retardation.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_26_2476=[""].join("\n");
var outline_f2_26_2476=null;
var title_f2_26_2477="Evaluation of sources of sepsis";
var content_f2_26_2477=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F59769&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F59769&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Evaluation of common sources of sepsis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Suspected site",
"       </td>",
"       <td class=\"subtitle1\">",
"        Symptoms/signs",
"       </td>",
"       <td class=\"subtitle1\">",
"        Microbiologic evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Upper respiratory tract",
"       </td>",
"       <td>",
"        Pharyngeal inflammation plus exudate &plusmn; swelling and lymphadenopathy",
"       </td>",
"       <td>",
"        Throat swab for aerobic culture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lower respiratory tract",
"       </td>",
"       <td>",
"        Productive cough, pleuritic chest pain, consolidative auscultatory findings",
"       </td>",
"       <td>",
"        Sputum of good quality, rapid influenza testing, urinary antigen testing (eg, pneumococcus, legionella), quantitative culture of protected brush or bronchoalveolar lavage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urinary tract",
"       </td>",
"       <td>",
"        Fever, urgency, dysuria, loin pain",
"       </td>",
"       <td>",
"        Urine microscopy showing pyuria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vascular catheters: arterial, central venous",
"       </td>",
"       <td>",
"        Redness or drainage at insertion site",
"       </td>",
"       <td>",
"        Culture of blood (from the catheter and a peripheral site), culture catheter tip (if removed)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Indwelling pleural catheter",
"       </td>",
"       <td>",
"        Redness or drainage at insertion site",
"       </td>",
"       <td>",
"        Culture of pleural fluid (through catheter), culture of catheter&nbsp;tip (if removed)&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wound or burn",
"       </td>",
"       <td>",
"        Inflammation, edema, erythema, discharge of pus",
"       </td>",
"       <td>",
"        Gram stain and culture of draining pus, wound culture not reliable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Skin/soft tissue",
"       </td>",
"       <td>",
"        Erythema, edema, lymphangitis",
"       </td>",
"       <td>",
"        Culture blister fluid or draining pus; role of tissue aspirates not proven",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Central nervous system",
"       </td>",
"       <td>",
"        Signs of meningeal irritation",
"       </td>",
"       <td>",
"        CSF microscopy, protein, glucose, culture, bacterial antigen test",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastrointestinal",
"       </td>",
"       <td>",
"        Abdominal pain, distension, diarrhea, and vomiting",
"       </td>",
"       <td>",
"        Stool culture for Salmonella, Shigella, and Campylobacter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intraabdominal",
"       </td>",
"       <td>",
"        Specific abdominal symptoms/signs",
"       </td>",
"       <td>",
"        Aerobic and anaerobic culture of percutaneously or surgically drained abdominal fluid collections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peritoneal dialysis (PD) catheter",
"       </td>",
"       <td>",
"        Cloudy PD fluid, abdominal pain, fever",
"       </td>",
"       <td>",
"        Cell count and culture of PD fluid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Genital tract",
"       </td>",
"       <td>",
"        <p>",
"         Women: Low abdominal pain, vaginal discharge",
"        </p>",
"        <p>",
"         Men: Dysuria, frequency, urgency, urge incontinence, cloudy urine, prostatic tenderness",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Women: Endocervical and high vaginal swabs onto selective media",
"        </p>",
"        <p>",
"         Men: Urine Gram stain and culture",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Joint",
"       </td>",
"       <td>",
"        Pain, warmth, decreased range of motion",
"       </td>",
"       <td>",
"        Arthrocentesis with cell counts, Gram stain, and culture&nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CSF: cerebrospinal fluid; PD: peritoneal dialysis.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Cohen J, Microbiologic requirements for studies of sepsis. In: Sibbald WJ, Vincent JL (eds), Clinical Trials for the Treatment of Sepsis, Springer-Verlag, Berlin, 1995, p.73.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_26_2477=[""].join("\n");
var outline_f2_26_2477=null;
var title_f2_26_2478="QT dispersion mortality normals";
var content_f2_26_2478=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F68172&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F68172&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 510px\">",
"   <div class=\"ttl\">",
"    QT dispersion predicts mortality",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 490px; height: 354px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a study of 1839 normal subjects followed for mean of 3.7 years, a corrected QT dispersion (QTD) &gt;58 msec was associated with a significantly increased all-cause (p = 0.018) and cardiovascular mortality (p = 0.0016) compared to a QTD &le;58 msec. Compared to a corrected QT interval (QTc) &le;460 msec, a QTc &gt;460 msec was also predictive of all-cause (p&lt;0.0001) and cardiovascular mortality (p&lt;0.014).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Okin PM, Devereux RB, Howard BV, et al. Circulation 2000; 101:61.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_26_2478=[""].join("\n");
var outline_f2_26_2478=null;
var title_f2_26_2479="Hemoglobin oxygen dissociation curve";
var content_f2_26_2479=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F81216&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F81216&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 518px\">",
"   <div class=\"ttl\">",
"    Oxyhemoglobin dissociation curve",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 498px; height: 470px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Depicted here is the oxyhemoglobin dissociation curve for normal adult hemoglobin (Hemoglobin A, solid line). Note that hemoglobin is 50 percent saturated with oxygen at a partial pressure of 27 mmHg (ie, the P50 is 27 mmHg) and is 100 percent saturated at a pO",
"    <sub>",
"     2",
"    </sub>",
"    of approximately 100 mmHg. Depicted here are curves that are \"left-shifted\" (blue line, representing increased oxygen affinity) and \"right-shifted\" (red line, decreased oxygen affinity). The effect of right- or left-shifting of the curve is most pronounced at low oxygen partial pressures. In the examples shown, the right-shifted curve means that hemoglobin can deliver approximately 70 percent of its attached oxygen at a pO",
"    <sub>",
"     2",
"    </sub>",
"    of 27 mmHg. In contrast, the left-shifted hemoglobin can deliver only about 35 percent of its attached oxygen at this pO",
"    <sub>",
"     2",
"    </sub>",
"    . A high proportion of fetal hemoglobin, which has high oxygen affinity, shifts this curve to the left in newborns.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_26_2479=[""].join("\n");
var outline_f2_26_2479=null;
